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ABSTRACT
Obesity increases the risk for several diseases, such as type 2 diabetes mellitus 
(T2DM), coronary heart disease (CHD), hypertension, osteoarthritis and certain 
cancers. In addition, obese individuals often have elevated blood pressure, increased 
levels of serum triglycerides (TG), free fatty acids (FFA) and insulin, as well as 
decreased serum high density lipoprotein cholesterol (HDL-C) levels. Twin, family 
and adoption studies suggest a major genetic component in the determination of 
body weight, although environmental factors also play a critical role in the 
development of obesity. 
In this thesis, we investigated the genetic background of obesity using several 
different approaches. In the first part of the thesis, two functional candidate genes, 
Melanocortin-4 receptor (MC4R) and Pro-opiomelanocortin (POMC) were screened 
for mutations in obese Swedish individuals. No obesity-causing mutations were 
identified.  However, we detected variations in the POMC gene associated with 
serum leptin levels in lean individuals. 
Second, we examined the possible role of the Lipin 1 (LPIN1) gene in humans. This 
gene was originally identified for lipodystrophy, hypertriglyceridemia and insulin 
resistance in the fld mice. Proper function of the Lpin1 gene is crucial for the normal 
adipose tissue differentiation, as well as for maintaining the glucose and lipid 
homeostasis in mice, thus presenting an interesting candidate gene for obesity and 
related metabolic disorders in humans. In the present study, the expression levels of 
LPIN1 in human fat biopsies correlated negatively with blood glucose and serum 
insulin levels. In addition, genetic variations of the LPIN1 gene were associated with 
serum insulin levels and body mass index (BMI) in dyslipidemic families, as well as 
in obese case and lean control individuals, males contributing the most to the 
differences. This is the first study suggesting the involvement of the LPIN1 gene in 
obesity and glucose metabolism in humans.  
Third, we fine mapped the region on chromosome Xq24 previously linked to obesity 
in obese Finnish families. Initially, linkage and shared haplotypes were identified in 
obese male sibpairs for this region. Subsequently, significant evidence of association 
between variations in the Solute carrier family 6 (neurotransmitter transporter) 
member 14 (SLC6A14) gene and obesity was observed in two different study 
populations. The SLC6A14 gene represents the second novel candidate gene for 
obesity, identified using the positional cloning approach in humans. 
In the fourth part of the thesis, we further investigated six chromosomal regions that 
have been previously linked to premature CHD, familial combined hyperlipidemia 
(FCHL), low HDL-C and obesity in Finnish families. We identified a novel 
quantitative trait locus (QTL) for HDL-C on chromosome 10q11. The markers in 
this region produced evidence of linkage with serum HDL-C levels, as well as 
provided evidence of association with serum HDL-C and TG levels, suggesting that 
the locus on chromosome 10q11 harbours variation(s) influencing the serum HDL-C 
and TG levels. 
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TIIVISTELMÄ 
Lihavuus on kasvava terveysongelma länsimaissa, koska lihavuus lisää 
huomattavasti riskiä sydän- ja verisuonitauteihin, aikuistyypin diabetekseen, 
nivelrikkoon ja tiettyihin syöpiin. Lihavuuteen liittyy myös keskeisiä 
aineenvaihdunnan häiriöitä, kuten kohonneet veren triglyseridi-, vapaa rasvahappo ja 
insuliinipitoisuudet, alentunut seerumin HDL-kolesterolipitoisuus sekä 
insuliiniresistenssiä. Suku-, kaksos- ja adoptiotutkimusten perusteella lihavuuden 
taustalla arvellaan olevan perintotekijöitä, jotka yhdessä ympäristön ja sosiaalisten 
tekijöiden kanssa määräävät kehon ilmiasun. 
Tämän tutkimuksen tavoitteena oli selvittää lihavuuden sekä siihen liittyvien 
aineenvaihdunnan häiriöiden molekyyligenetiikkaa suomalaisessa ja ruotsalaisessa 
väestössä. Väitöskirjatyön ensimmäisessä osassa tutkimme sairaanloisen lihavan 
ruotsalaisen potilaan joukkoa tarkoituksena selvittää kuinka yleisiä lihavuuden 
selittäjiä melanokortiini-4 reseptori (MC4R)- ja pro-opiomelanokortiini (POMC)- 
geenien mutaatiot ovat. Yhtään lihavuuden selittävää muutosta ei näistä geeneistä 
tästä potilasjoukosta löytynyt. Sen sijaan yhden nukleotidin muutokset (single 
nucleotide polymorphism=SNP) POMC-geenissä olivat yhteydessä alentuneeseen 
leptiinipitoisuuteen normaalipainoisilla henkiloillä. 
Väitöskirjan toisessa osassa tavoitteena oli selvittää lipin 1 (LPIN1)-geenin
merkitystä painonsäätelyssä sekä sokeri-ja rasva-aineenvaihdunnan häiriöiden 
synnyssä suomalaisessa väestössä. LPIN1-geeni ilmenee rasvakudoksessa ja on 
välttämätön rasvasolujen normaalin kehityksen ja erilaistumisen kannalta. Lpin1-
geenin mutaatio aiheuttaa hiirellä rasvakudoksen puutoksen, korkeita veren 
triglyseriditasoja (hypertriglyseridemiaa) ja insuliiniresistenssiä. Tässä 
tutkimuksessa tutkimme LPIN1-geenin ilmentymistä rasvakudoksessa sekä LPIN1-
geenin sisäisiä ja geeniä ympäröivän alueen DNA-muutoksia lihavien ja 
normaalipainoisten henkilöiden tapaus-verrokkiaineistossa sekä perheaineistossa, 
jossa on useita familiaarista kombinoitua hyperlipidemiaa (FKH-tautia) sairastavia 
potilaita jokaisessa perheessä. Havaitsimme LPIN1-geenin ilmentymisen 
rasvakudoksessa olevan yhteydessä seerumin insuliini- ja sokeritasoihin sekä geenin 
sisäisten DNA-muutosten assosioituvan seerumin insuliipitoisuuksiin sekä 
painoindeksiin erityisesti miehillä. Tutkimus on ensimmäisen osoitus LPIN1-geenin 
yhteydestä lihavuuteen ja sokeriaineenvaihdunnan säätelyyn ihmisillä. 
Väitöskirjan kolmannessa osatyössä tarkkakartoitettiin suomalaisessa aineistossa 
lihavuuteen kytkeytynyt kromosomialue kromosomissa Xq24. Tutkimalla 
suomalaisessa lihavien sisarusparien aineistossa perimän monimuotoisia markkereita 
sekä geeninsisäisiä SNP:ja alueen lupaavimmista lihavuuden ehdokasgeeneistä 
rajasimme alueen noin neljän megaemäksen (=4 miljoonaa nukleotidia) laajuiseksi. 
Tutkiessamme tämän alueen jaettuja haplotyppejä ja testatessamme alueen 
ehdokasgeenejä tapaus-verrokkiaineistossa löytyi lihavuuteen assosioituva SNP 
solute carrier family 6 member 14 (SLC6A14) -geenin 3’-päästä sekä SNP-
haplotyyppi SLC6A14-geenin ympäriltä. Myös Suomesta ja Ruotsista kerätyssä 
replikaatioaineistossa näkyi ero alleelifrekvensseissä lihavien ja normaalipainoisten 
henkilöiden välillä SLC6A14-geenin sisäisen SNP:n kohdalla. SLC6A14-geeni on 
toinen lihavuuteen yhdistetty geeni, joka on löytynyt koko genomin haun tuloksena. 
Väitöskirjatyön viimeisessä osassa tutkittiin koko perimän geenihauissa lihavuuteen, 
sepelvaltimotautiin, FKH-tautiin, pieneen seerumin HDL-kolesterolipitoisuuteen ja 
korkeaan triglyseridipitoisuuteen kytkeytyviä kromosomialueita (2q31, 8q23, 10q11, 
16q24.1-24.2, 20q13.11, Xq24). Edellä mainitut fenotyypit liittyvät myös tiiviisti 
yhteen; lihavuus altistaa sepelvaltimotautiin ja toisaalta, lihavuuteen, kuten myös 
sepelvaltimotautiin, liittyvät yleensä kohonneet seerumin kolesteroli- ja 
triglyseridiarvot ja onkin mahdollista, että näiden fenotyyppien taustalla on yhteisiä 
altistavia geneettisiä tekijöitä. Totesimme tässä työssä HDL-kolesterolipitoisuuden 
kytkeytyvän kromosomiin 10q11. Lisäksi kromosomi 10q11 alueen markkerit 
assosioituivat matalaan HDL-kolesterolipitoisuuteen sekä kohonneisiin 
triglyseridipitoisuuksiin viitaten mahdollisesti yhteisiin altistaviin DNA-muutoksiin. 
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ABBREVIATIONS
BMI  body mass index 
CHD  coronary heart disease 
CVCD  common variant, common disease 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 
FCHL  familial combined hyperlipidemia 
FFA  free fatty acid 
GAD2  glutamate decarboxylase 1 
HDL-C  high density lipoprotein cholesterol 
HGP  Human Genome Project 
IBD  identical by descent 
IBS  identical by state 
LD  linkage disequilibrium 
LDL-C  low density lipoprotein cholesterol 
lod  logarithm of odds 
LPIN1 lipin 1
MC4R  melanocortin-4 receptor 
NCEP: ATP III  National Cholesterol Education Program’s Adult Treatment Panel 
III
POMC  pro-opiomelanocortin 
PPARG  peroxisome proliferative activated receptor-?
QTL  quantitative trait locus 
SLC6A14 solute carrier family 6 (neurotransmitter transporter) member 14
SNP  single nucleotide polymorphism 
SSCP  single-strand conformation polymorphism 
TC  total cholesterol 
TDT  transmission/disequilibrium test 
TG  triglyceride 
T2DM  type 2 diabetes mellitus 
UTR  untranslated region 
WHO  World Health Organization 
WHR  waist-to-hip ratio  
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INTRODUCTION
Obesity, or in other words excess accumulation of body fat, is a serious health problem 
in the Western societies due to the increased risk for related disorders such as type 2 
diabetes mellit us (T2DM, Chan et al. 1994; Colditz et al. 1995), coronary heart 
disease (CHD, Hubert et al. 1983; Willett et al. 1995; Hu et al. 2005), hypertension 
(Huang et al. 1998), osteoarthritis (Felson 1996) and certain cancers (Calle et al. 
2003). Obese individuals have three times higher risk for CHD (Willett et al. 1995) 
and up to 40 times higher risk for T2DM when compared to lean individuals (Chan et 
al. 1994; Colditz et al. 1995). Because of the serious health consequences related to 
obesity, it is of great interest to discover the factors predisposing to obesity, in order to 
create efficient prevention and treatment for obesity. 
Body weight is determined by the complex interplay between genetic and 
environmental factors. Obesity aggregates in families, but the pattern of inheritance 
does not in most cases follow any Mendelian form of segregation. Common forms of 
obesity are thus most likely to be caused by multiple genetic and environmental 
factors, and by their interactions. 
What kind of genetic variants predispose to common complex diseases  
such as obesity? Multiple common alleles with minor effects have been suggested to 
form disease susceptibility to common complex diseases (Collins et al. 1997). 
Alternatively, rare alleles with strong phenotypic effects may underlie the genetic 
background for common diseases (Pritchard 2001). Genes responsible for common 
forms of obesity can also represent so-called ‘thrifty genes’ (Neel 1962). These gene 
variants may have provided a survival advantage during evolution at times when there 
were frequent periods of food shortage or famines. However, within the last decades, 
as the food supply has been constant and plentiful for the first time in human history, 
these gene variants have become detrimental, predisposing to common diseases, such 
as overweight, obesity and T2DM, typical to Western societies. 
The purpose of this study was to investigate the genetic background of obesity. The 
completion of the Human Genome Project (HGP, Collins et al. 2003) and advances 
in technologies and statistical methods have provided the basic tools for effective 
gene identification in complex traits. The following review will focus on the existing 
knowledge of the genetic background of human obesity and on strategies utilized in 
the post-genome area to identify genes conferring susceptibility to common forms of 
obesity and related metabolic disorders. 
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REVIEW OF LITERATURE 
1 OBESITY – PREVALENCE, RISK FACTORS AND 
HEALTH CONSEQUENCES 
1.1 Definition and prevalence of obesity 
Obesity can be described as an excess amount of fat tissue accumulated as a result of 
imbalance between energy intake and energy expenditure. A simple way to measure 
obesity is by using the body mass index (BMI), which is calculated by dividing 
person’s weight in kilograms by square of person’s height in meters. The cut-off points 
proposed by the World Health Organization (WHO) for defining obesity are shown in 
table 1 (World Health Organization 1995; World Health Organization 1997). 
Table 1. Definitions of normal weight and obesity according to the World Health 
Organization (WHO 1995; 1997). 
BMI (kg/m2) WHO Classification Popular description 
< 18.5 Underweight Thin 
18.5-24.9 Normal range Healthy, normal, acceptable 
25.0-29.9 Grade 1 overweight Overweight 
30.0-39.9 Grade 2 overweight Obesity 
? 40.0 Grade 3 overweight Morbid obesity 
* Body mass index (BMI) 
The BMI is a crude measure of adiposity but correlates well with body fatness (Gray 
and Fujioka 1991; Strain and Zumoff 1992; Steinberger et al. 2005). Other 
anthropometric measures include waist and hip circumference or the ratio of them 
(waist-to-hip ratio = WHR). There are more accurate measures to estimate adiposity, 
including bioimpedance analysis, under water weighing, dual-energy X-ray 
absorptiometry, measurements of skin fold thickness, and imaging methods, such as 
computed tomography and magnetic resonance imaging. Since these techniques are 
often more laborious and expensive, they are not as popular in routine use, whereas 
information to calculate the BMI is usually easily available. The BMI also correlates 
with obesity related risk factors (Willett et al. 1999; Steinberger et al. 2005), making 
it the most frequently used method to evaluate obesity. Recently, waist 
circumference has been suggested to be even better predictor of obesity-related 
diseases than BMI (Janssen et al. 2004). In addition, the cut-off points proposed by 
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WHO mainly for the Western societies may not be optimal to all different ethnicities 
(WHO Expert Consultation 2004; Tan et al. 2004). 
There are large differences between countries in the prevalence of obesity 
(Kopelman 2000). However, obesity has become increasingly prevalent both in 
Western societies and in developing countries (Bjorntorp 1997; Kopelman 2000; 
Flegal et al. 2002). The prevalence of obesity is high for example in Eastern Europe, 
Eastern Mediterranean, North, Central and South America (especially in the US, 
Argentina, Chile, Paraguay and Mexico), as well as in many Western European 
countries (Kopelman 2000; James et al. 2001; James 2004). There are certain 
isolated Pacific Islands such as Samoa, Nauru, Tonga, the Cook Islands and French 
Polynesia where obesity is extremely common with a prevalence close to 75% 
(Bjorntorp 1997). Within some of these ethnic groups large physical size is still 
considered as a mark of beauty and social status. 
The marked increase in the prevalence of obesity in the US during the last 20 years 
is well documented in the reports of the Behavioral Risk Factor Surveillance System, 
conducted annually in the US by the Centers for Disease Control and Prevention 
(http://www.cdc.gov/nccdphp/dnpa/obesity/trend/) (Li et al. 2005). Data collected for 
1999-2002 estimates that 30.4% of the adult US population has a BMI more than 30 
kg/m2 and is thus considered obese (Hedley et al. 2004). This number has almost 
doubled when compared to the results from the same survey in 1976-1980. 
In Finland, according to the national FINRISK 2002 survey, 20.4% of men and 
18.9% of women had a BMI more than 30 kg/m2, and were thus co nsidered obese 
(Laatikainen et al. 2003). The mean BMI in men was 27 kg/m2 and in women 25.9 
kg/m2 in 2002, see figure 1. There are interesting gender-differences in trends of 
obesity in Finland, as the mean BMI in males has been increasing steadily since 
1972, and on average the obesity of men exceeds the obesity of women (Lahti-Koski 
et al. 2001). In females the mean BMI actually dropped in 1970’s, but has increased 
again since 1980’s. This is opposite to what is seen in most other Western countries 
where women are generally both more obese and overweight than men (Flegal et al. 
2002; Baskin et al. 2005). The increased prevalence of obesity coincides with 
industrialization and automation of societies. Compared to the past decades, the 
physical effort in daily labors has been minimized, as the work has become 
increasingly sedentary. It can be speculated that during the last couple of decades 
highly educated Finnish women have recognized the social pressure for slimness and 
learned to control their weight (Sarlio-Lahteenkorva et al. 2004). At the same time 
the social pressure has not been as strong on men, and this combined with a decrease 
in the energy expenditure at work has resulted in the tendency of men to continue 
gaining weight. 
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Figure 1. The mean body mass index (BMI) among men and women in Finland 
during the years 1972-2002 (Lahti-Koski et al. 2001; Laatikainen et al. 2003). 
1.2 Factors predisposing to obesity 
Body weight is the result of the complex interplay between genetic, environmental 
and psychosocial factors acting through the physiological mediators of energy intake 
and energy expenditure (figure 2). Environmental factors must play a significant role 
in obesity, as evidenced by increasing prevalence of obesity in the last decade. A 
sedentary life style and low physical activity promote obes ity (Rissanen et al. 1991). 
Body weight also increases with age (Rahkonen et al. 1998). Of the dietary factors, 
high fat content and energy density have been associated with obesity (Lindroos et 
al. 1997; Bray and Popkin 1998; McCrory et al. 2000; Bray et al. 2004). An 
association between low socioeconomic status and obesity has also been reported 
(Kahn and Williamson 1990; Rissanen et al. 1991; Rahkonen et al. 1998; Sarlio-
Lahteenkorva et al. 2004). In addition, overweight individuals more often have 
difficulties controlling eating, have stronger feeling of hunger, and they tend to 
engage in emotional eating (Lindroos et al. 1997; Hakala et al. 1999). 
However, in a similar, shared environment some people are likely to become obese, 
whereas others are not. Twin, family and adoption studies suggest a major genetic 
component in the determination of body weight (see page 34) (Stunkard et al. 1986; 
Stunkard et al. 1990; Sorensen et al. 1992a; Sorensen et al. 1992b; Vogler et al. 
1995; Allison et al. 1996b; Maes et al. 1997; Rice et al. 1999). Cur rently, obesity is 
thus seen as a complex disorder with an individual’s genetic background affecting 
the susceptibility, but ultimately genetic, physiological and psychosocial factors 
acting together to determine the body composition (figure 2). 
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Figure 2. Factors affecting body weight.
1.3 Health consequences of excess body weight 
The increased public and scientific attention to obesity is largely due to its health 
consequences. Total mortality associated with BMI shows a J shaped curve (figure 
3), meaning that overweight and obesity, as well as underweight, are associated with 
increased total mortality (Manson et al. 1995; Flegal et al. 2005). Increased death in 
underweight individuals is largely due to smoking (Manson et al. 1995). The 
increased death in obese individuals can be explained by chronic diseases that are 
more common in obese than in normal weight individuals (Willett et al. 1999; 
Kopelman 2000). T2DM (Chan et al. 1994; Colditz et al. 1995; Rimm et al. 1995), 
CHD (Hubert et al. 1983; Willett et al. 1995; Hu et al. 2005), hypertension (Huang et 
al. 1998), cholelithiasis (Maclure et al. 1989), certain forms of cancer (Calle et al. 
2003) and osteoarthritis (Felson 1996) are the most common disorders associated 
with obesity. 
The risk for CHD was two times higher in overweight women compared to lean 
individuals (BMI < 21 kg/m2) and more than three times higher in women with BMI 
> 29 kg/m2 (Willett et al. 1995). The risk for T2DM goes up even more dramatically 
with increasing BMI. Obese females with BMI > 31 kg/m2 have about 40 times 
higher risk for T2DM compared to lean individuals with BMI < 22 kg/m2 and more 
than 90 times higher risk when BMI exceeds 35 kg/m2 (Colditz et al. 1995). In 
males, the association between obesity and T2DM has been detected, too; when BMI 
exceeds 35 kg/m2, the risk for T2DM is more than 40 times greater when compared 
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to lean individuals (Chan et al. 1994). The significant increase in risk for T2DM can 
be seen even in normal weight pe ople, especially in the case of women; the risk for 
T2DM is increased five times with BMI 24-25 kg/m2 compared to women with BMI 
< 22 kg/m2 (Chan et al. 1994; Colditz et al. 1995). The weight change also affects 
the risk for T2DM; loss of approximately 10 kg decreases the risk 1.4 times, whereas 
gaining the same amount of weight increases the risk 2.2 times. (Tuomilehto et al. 
2001). The types of cancers associated with obesity include breast cancer in 
postmenopausal women, as well as cancers of colon, endometrium, kidney, 
oesophagus, gastric, pancreas, gallbladder and liver (Calle et al. 2003; Calle and 
Kaaks 2004). 
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Figure 3. The association between body mass index (BMI) 
and total mortality and factors suggested explaining it. 
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The location where fat accumulates in body has an effect on disease susceptibility, 
the abdominal fat being more risky than subcutaneous fat (Janssen et al. 2004; 
Borodulin et al. 2005). In this respect, measuring the waist circumference or the 
WHR may be more accurate in defining the individual’s risk. 
Because of the serious health consequences related to overweight and the large 
resources that the obesity-related diseases require on the health care system, it is of 
great interest to discover the mechanisms that predispose to obesity, as well as to 
create efficient prevention and treatment for obesity. 
2 METABOLIC DISORDERS RELATED TO OBESITY 
2.1 Metabolic consequences of obesity 
Obese individuals often have elevated insulin levels and are insulin resistant (Pascot 
et al. 2001). A major contributor to the insulin resistance is excess free fatty acids 
(FFA, Eckel et al. 2005). FFAs are derived from the triglyceride (TG) stores in the 
adipose tissue through the action of hormone sensitive lipase and from the TG-rich 
lipoproteins by the action of lipoprotein lipase. Normally, insulin inhibits the 
lipolysis in adipose tissue. Thus, more fatty acids are released from the adipose 
tissue when insulin resistance develops. The lipotoxic effects of excess FFAs may 
occur via increased fatty acid oxidation instead of the utilization of glucose for 
energy in peripheral tissues (Randle et al. 1963). Alternatively, FFAs may inhibit 
insulin signaling including phosphorylation of the insulin receptor substrates and, 
thus, decrease glucose transport across the cell membrane (Dresner et al. 1999). 
Obese individuals often have elevated serum TG (Devroey et al. 2004), total 
cholesterol (TC, Gregg et al. 2005) and FFA (Pankow et al. 2004), as well as 
decreased high density lipoprotein cholesterol (HDL-C) levels (Devroey et al. 2004). 
In the circulation, most lipids are transported as water-soluble lipoproteins that 
consist of a hydrophopic core of TGs and cholesterol-esters surrounded by more 
hydrophilic surface of cholesterol, apolipoproteins and phospholipids. Lipoproteins 
are separated into five major classes according to their densities. These classes 
include chylomicrons, VLDL, intermediate density lipoproteins (IDL), LDL and 
HDL. Chylomicrons mainly deliver the exogenous lipids to peripheral tissues, 
whereas the VLDL is the transporter of the endogenously produced TGs and 
cholesterol. After losing its TGs by the action of lipoprotein lipase, VLDLs are 
transformed into IDL and further to cholesterol-rich LDL particles. HDL particles 
are mainly responsible for the reverse cholesterol transport, i.e., they transport the 
excess cholesterol from the peripheral tissues to liver. Nascent HDL particles are 
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synthesized in liver and intestine. These discoidal lipid-free HDL particles absorb 
intracellular cholesterol from the peripheral tissues and mature while acquiring 
cholesterol esters via esterification of free cholesterol by lecithin:cholesterol 
acyltransferase. 
Dyslipidemic features in obese individuals are related to both lipoprotein 
concentrations, as well as to lipoprotein composition (Eckel et al. 2005). Increased 
fatty acid availability in the liver results in increased synthesis of TGs, which further 
promotes the formation of apolipoprotein B-containing VLDL particles. Decreased 
HDL-C levels in the circulation are associated with increased TG levels (Despres et 
al. 2000). This may have resulted from the action of cholesterol ester transfer 
protein, which mediates the exchange of TG from VLDL to HDL and cholesterol 
esters from HDL to VLDL (Eckel et al. 2005). The net effect is the enrichment of 
HDL particles with TGs and depletion of cholesterol esters, in addition to reduced 
size of HDL particles, which may enhance the clearance of the HDL particles from 
the circulation. The content of LDL particles is modified resulting in formation of 
small dense LDL particles that are more readily oxidized and highly atherogenic.  
Visceral fat has been implicated as a specific source of FFAs (Moller and Kaufman 
2005). It is more metabolically active and has higher rate of lipolysis than subcutaneous 
fat, possibly explaining why central obesity could be even better predictor of obesity-
related diseases than BMI alone. Interestingly, normal-weight individuals with insulin 
resistance have increased visceral adipose tissue (Ruderman et al. 1998). Increased waist 
circumference is associated with increased obesity-related health risks in overweight, 
obese, as well as in normal individuals (Janssen et al. 2004). The metabolic effects of 
increased visceral fat may be me diated throught the production of adipocyte-derived 
proteins, including for instance adiponectin and resistin. 
The hypertension associated with obesity may be mediated through elevated insulin 
levels and insulin resistance (Huang et al. 1998). In normal weight individuals, 
insulin is a vasodilator, but the vasodilating effect may be lost in obesity (Eckel et al. 
2005). This combined with enhanced renal sodium retention in obese individuals and 
increased symphathetic nervous system activity may drive hypertension. 
2.2 The metabolic syndrome 
Obesity, especially central obesity, insulin resistance, dyslipidemia and hypertension 
co-occur in the same individuals more often than expected by chance alone and are 
collectively referred to as the metabolic syndrome (Eckel et al. 2005). Diagnostic 
criteria for the metabolic syndrome have been suggested by four different 
committees: the WHO (Alberti and Zimmet 1998; Alberti et al. 2005), the European 
Group for the Study of Insulin Resistance (Expert Panel on Detection Evaluation, 
and Treatment of High Blood Cholesterol in Adults 2001), the National Cholesterol 
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Education Program’s Adult Treatment Panel III (NCEP: ATP III, Balkau and 
Charles 1999) and the International Diabetes Federation (IDF, http://www.idf.org/).
They agree on the essential diagnostic components including glucose intolerance, 
obesity, hypertension and dyslipidemia, but differ in the emphasis on different 
elements and their cut-off points. Criteria from the WHO and the European Group 
for the Study of Insulin Resistance highlight insulin resistance as the core 
component, whereas, the NCEP: ATP III considers that all components are equally 
important. IDF focuses on central obesity and has suggested ethnic-specific cut-off 
points for waist circumference. These criteria are presented in table 2. 
Table 2. The three different criteria for the metabolic syndrome suggested by the World 
Health Organization (WHO), the European Group for the Study of Insulin Resistance 
and the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP: 
ATP III). 
World Health 
Organization 
European Group 
for the Study of 
Insulin Resistance 
National Cholesterol 
Education Program’s 
Adult Treatment 
Panel III 
International
Diabetes 
Federation  
• Diabetes or impaired 
fasting glycaemia or 
impaired glucose 
tolerance or insulin 
resistance
(hyperinsulinaemic,
euglycaemic clamp-
glucose uptake in 
lowest 25%) 
•  Plus 2 or more of the 
following 
   - Obesity: BMI > 30 
or WHR > 0.9 (male) 
or > 0.85 (female) 
   - Dyslipidaemia: 
TGs ?  1.7 mmol/L or 
HDL-C < 0.9 (male) or 
< 1.0 (female) mmol/L 
   - Hypertension: 
blood pressure > 
140/90 mm Hg 
   - Microalbuminuria: 
albumin excretion > 20 
?g/min
• Insulin resistance -
hyperinsulinaemia:
top 25% of fasting 
insulin values from 
non-diabetic
population
•  Plus 2 or more of 
the following 
   - Central obesity: 
waist circumference ?
94 cm (male) or ?  80 
cm (female) 
   - Dyslipidaemia: 
TGs > 2.0 mmol/L or 
HDL-C < 1.0 
   - Hypertension: 
blood pressure ?
140/90 mm Hg and/or 
medication
   - Fasting plasma 
glucose ? 6.1 mmol/L 
• 3 or more of the 
following:
   - Central obesity: 
waist circumference > 
102 cm (male), > 88 cm 
(female)
   - Hypertriglycerid-
aemia: TGs ?  1.7 
mmol/L
   - Low HDL-C: 
< 1.0 mmol/L (male), 
< 1.3 mmol/L (female) 
   - Hypertension: blood 
pressure ?  135/85 
mm Hg or medication 
   - Fasting plasma 
glucose ?  6.1 mmol/L 
• Central obesity: 
waist circumference 
with ethnic-specific 
cut-off points 
• Plus 2 or more of the 
following 
   -Hypertriglycerida-
emia: TGs ?  1.7 
mmol/L or medication 
   - Low HDL-C: 
< 1.03 mmol/L (male), 
< 1.29 mmol/L 
(female) or medication 
   - Hypertension: 
blood pressure ?
135/85 mm Hg or 
medication
   - Fasting plasma 
glucose ?  5.6 mmol/L 
or diagnosed T2DM
Abdominal obesity or the so-called hypertriglyceridemic waist phenotype has also 
been suggested to be the central component of the metabolic syndrome (Frayn 
2005), while others consider insulin resistance to be the culprit of the condition 
(Eckel et al. 2005). Thus far the key component of the metabolic syndrome is still 
not clear. In figure 4 Eckel et al. (2005) depict the role of excess FFAs in promoting 
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insulin resistance as a starting point of the metabolic abnormalities. Excess FFAs 
released from the adipose tissue promote glucose, TG and very low density 
lipoprotein production in the liver. This is associated with decreased HDL-C and 
increased low density lipoprotein cholesterol (LDL-C) in the circulation. Increased 
FFA levels reduce insulin sensitivity in muscle by inhibiting insulin-mediated 
glucose uptake. This in turn increases TG accumulation in muscle tissues and 
reduces the glucose portioning to glycogen. Increased plasma glucose levels promote 
insulin secretion from the pancreas resulting in hyperinsulinemia. Hyperinsulinemia 
may also enhance sodium reabsorption and increase the activity of sympathetic 
nervous system contributing to hypertension. 
VLDL
GLUCOSE
INSULIN
FFA
FFA
TGs
(intramuscural
droplets)
HYPERTENSION
HDL-C ?
SMALL DENSE LDL?
INSULIN
Glycogen ?
Sympathetic 
nervous system
Figure 4. The key organs in development of the metabolic syndrome. The release of 
excess free fatty acids (FFA) from visceral or peripheral adipose tissue has effects on 
lipid and glucose metabolism in multiple organs. In the liver, FFAs promote the 
production of glucose, triglycerides (TG) and very low density lipoprotein (VLDL). This 
reduces high density lipoprotein-cholesterol (HDL-C) levels and increases the amount of 
small dense low density lipoprotein (LDL) particles in the circulation. In muscle, FFAs 
inhibit insulin-mediated glucose uptake, which in turn increases TG accumulation in 
muscle. Increased plasma glucose levels increase insulin secretion from the pancreas, 
which may promote sodium reabsorption and contribute to hypertension. Modified from 
Eckel et al. (2005). 
22
2.3 Phenotypic overlap between obesity, T2DM and 
atherosclerosis
Clinical diagnosis of the metabolic syndrome has been suggested as a means to 
identify individuals susceptible to obesity, T2DM, familial combined hyperlipidemia 
(FCHL) and CHD. The metabolic syndrome was approximately five times more 
common in overweight (BMI > 25 kg/m2) and 30 times more common in obese 
individuals (Katzmarzyk et al. 2005). In young adults, small increases in BMI, as 
well as insulin resistance, were associated with the metabolic syndrome (Weiss et al. 
2004). On the hand, CHD events were three times more likely in individuals with the 
metabolic syndrome (Isomaa et al. 2001; Lakka et al. 2002). Patients with the 
metabolic syndrome were five to eight times more likely to develop T2DM 
(Laaksonen et al. 2002). In addition, abnormal lipid levels were observed in more 
than half of the premature CHD patients, the low HDL-C levels being the most 
common dyslipidemia (Genest et al. 1992). To conclude, there is phenotypic overlap 
between obesity, T2DM, CHD and the metabolic syndrome, as these conditions 
occur in an individual more often than expected by chance.
3 STRATEGIES TO IDENTIFY GENES PREDISPOSING 
TO OBESITY AND RELATED METABOLIC 
DISORDERS IN THE POST-GENOME AREA 
3.1 Complexity of contributing factors in obesity and related 
metabolic disorders 
3.1.1 Allelic spectra of disease variants 
Multiple genetic and environmental risk factors most likely confer susceptibility to 
complex diseases, including obesity and related metabolic disorders. Each risk factor 
may only have a minor-to-modest effect on this susceptibility. In addition to the 
phenotypic complexity due to the overlap of obesity and related metabolic disorders, 
many other factors complicate the identification of the genetic background of 
obesity. These factors, listed in table 3, hamper the identification of genes for other 
complex traits, too. 
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Table 3. Multiple factors complicate the identification of the underlying genes for 
complex disorders. These factors are related to the unknown allelic architecture of the 
predisposing alleles, difficulties in defining the phenotype, technical issues in 
genotyping, and statistical analyses. 
Unknown allelic spectra Unknown allele frequency 
 Unknown mode of inheritance 
 Unknown quantity of risk provided 
 Epistasis 
 Genetic heterogeneity 
Phenotype Difficulties in diagnosis 
 Late onset of the disease 
 Pleiotrophy 
 Phenocopies 
 Incomplete penetrance or variable expression of the 
phenotype  
 Quantitative phenotypes 
Technical issues Affordable large-scale genotyping methods  
Statistical analyses Multiple testing 
 Limited statistical power 
Publication bias A tendency to publish results that appear significant, 
because negative or near neutral results do not arouse 
enough interest 
It is still debatable what kind of allelic spectrum of the disease alleles underlies 
common complex diseases (Botstein and Risch 2003; Pajukanta 2004). Common 
complex diseases do not follow classic Mendelian inheritance patterns that are the 
dominant, recessive or X-linked mode of inheritance. Thus, they are unlikely to be 
caused by single gene defects. Several different hypotheses of the allelic spectra of 
the common complex diseases have emerged. The most well-known hypothesis 
suggests that the disease-predisposing alleles occur frequently in the population and 
each of them contributes little to disease susceptibility. This is known as the 
common variant, common disease (CVCD) hypothesis (Collins et al. 1997). The 
alternative heterogeneity model suggests that rare alleles with strong phenotypic 
effects may underlie the genetic background for common diseases. According to the 
so-called neutral hypothesis, the allelic spectrum of common diseases is similar to 
that of the allelic spectrum of all the variants in the genome (Wang et al 2005). The 
potential allelic spectra according to these three hypotheses are presented in figure 5. 
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Figure 5. The depiction of three hypothetical distributions of the allelic spectra of the 
common diseases. The common variant, common disease (CVCD) hypothesis suggests a 
large number of high frequency variants. According to the classical heterogeneity model, 
more rare variants are expected and, thus, more genetic heterogeneity is expected in the 
population. The solid line shows an estimated allelic spectrum in the whole genome, 
regardless of whether the variants are disease-causing or not. Modified from Wang et al. 
(2005). 
In addition to the sample size requirements, the allelic spectrum of the disease in 
question is important in sampling strategies. Different patterns of decline in disease 
risk among relatives can be expected for diseases with major gene effects compared 
to multiple genes with minor effects. In theory, the correlation of traits between 
related subjects should decrease linearly with distancing of relatedness, if few rare 
variants with additive and independent effects underlie the disease (Wang et al. 
2005). In contrast, in the case of multiple alleles with minor and potentially 
interdependent effects, the risk may decline more rapidly with a decrease in 
relatedness. In addition, more genetic heterogeneity is expected in pedigrees when 
more distant relatives are included. 
3.1.2 Genetic forces driving the allelic spectra 
Very few disease genes for complex diseases have been identified so far, making it 
difficult to evaluate the accuracy of each model (for examples of the genes 
associated with obesity and related metabolic disorders, please see pages 39 and 40). 
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Certain evolutionary phenomena may have driven the allelic spectra in different 
directions. Negative selection reduces the frequency of the alleles that have 
deleterious effects on the phenotype. As a result of the negative selection, the disease 
alleles should have a low frequency. Positive selection refers to the effect of 
evolutionary forces that favor certain variants and increases their allele frequencies. 
Positive selection should result in the common variants conferring more frequently 
to disease susceptibility. In addition, certain variants that cause disease in 
homozygous form are known to be beneficial in the heterozygous state, i.e., possess 
a heterozygote advantage. Because of the heterozygote advantage these variants 
remain frequent in the population. For example, the variant causing sickle cell 
anemia in homozygotes is protective against malaria infection in heterozygotes 
(Ashley-Koch et al. 2000). Random genetic drift has little effect in a large 
population, whereas, in a small isolated population genetic drift or random sampling 
of gametes may have an impact on allele frequencies. The knowledge of the allelic 
spectra typical of common complex diseases would be very helpful when designing 
statistically powerful studies for disease gene identification. 
3.1.3 The risk associated with the disease variants 
Another important feature of a disease variant is the amount of risk that it carries. 
The associated risk has been in most cases small for the disease variants identified so 
far, with magnitudes of odds ratios of 1,1-2 (Lohmueller et al. 2003). For example, 
the common pro12-allele of the pro12ala polymorphism in the Peroxisome 
proliferative activated receptor-? (PPARG) gene has been associated with T2DM 
(Altshuler et al. 2000). The carriers of the more common pro12-allele have been 
estimated to exhibit a 1.25-fold increase in risk for T2DM, as reported in a meta-
analysis evaluating 16 previously published studies (Altshuler et al. 2000). The small 
increase in disease risk makes the search for variants difficult, since large sample 
sizes are necessary to detect statistically significant differences. Although risk for an 
individual is small, the population attributable fraction may, however, be large when 
taking into account the allele frequency of a variant. Thus, the variant may explain a 
considerable portion of the risk in population. In the case of pro12ala polymorphism 
of the PPARG gene, the population attributable fraction is estimated to be as high as 
25%, because of the high frequency of the disease predisposing allele (Altshuler et 
al. 2000). 
3.2 Human Genome Project 
One major obstacle or at least laborious task in disease gene mapping used to be the 
creating of complete genetic and physical maps of the region of interest. However, 
this problem has recently been largely solved, as the public Human Genome Project 
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(HGP) and the private Celera Company have provided a comprehensive map of the 
human genome (Venter et al. 2001; Collins et al. 2003). 
The HGP started nearly two decades ago when an international multicenter program 
set an ambitious goal to define the nucleotide sequence of the human genome, in 
order to understand the genes and the genetic constitution of human beings. In the 
beginning, a lot of emphasis was placed on developing and improving technologies 
for genome research and providing better genetic and physical maps of the genome. 
When genome sequencing had proceeded to the point where 90 percent of the 
genome's three billion base-pairs were sequenced, first part of the results was 
published in February 2001 (Lander et al. 2001). This was accompanied with the 
surprising news that the human genome only consisted of approximately 30,000 
genes (Lander et al. 2001). At the same time, the sequence of the human genome 
was also published by the Celera company (Venter et al. 2001), which recently made 
the sequence information freely available. 
This enormous sequencing project was completed in 2003, two years ahead of the initial 
schedule, and an accurate and complete human genome sequence was made available to 
the research community (Collins et al. 2003) http://www.ncbi.nlm.nih.gov). The 
surprisingly low number of human genes, current estimation 20.000-25.000 
(International Human Genome Sequencing Consortium 2004), as compared to other 
species, suggested that the function and understanding of the genome is far beyond the 
sequence itself (Carninci et al. 2005; Katayama et al. 2005). 
3.3 Statistical methods of gene identification 
3.3.1 Phenotypes
The phenotypic traits of interest are usually qualitative, i.e., the disease is present or 
not (for example obesity) or quantitative, i.e. the trait values are continuous (for 
example BMI). Certain cut-off points can be applied to the quantitative traits to 
convert them into qualitative. For example, individuals with BMI equal to or more 
than 30 kg/m2 can be considered obese (WHO 1995; 1997). 
3.3.2 Linkage analysis 
A commonly used approach in disease gene mapping is to study families with 
multiple affected individuals, in order to identify chromosomal regions linked to 
disease. In linkage studies, the chromosomal location of the gene predisposing to the 
disease is searched by monitoring co-segregation of a genetic marker with the trait in 
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pedigrees. Statistical approaches in linkage studies can be divided into parametric 
and non-parametric. 
Linkage analysis determines whether the disease and the polymorphic marker loci 
co-segregate in a pedigree more often than if the marker was not located physically 
near the disease mutation. The overall likelihood of the data for two alternative 
assumptions is calculated in the linkage analysis; first, that the two loci are linked 
with the given recombination fraction (?); second, that they are not linked. The 
logarithm to the base 10 of the ratio of these two likelihoods is the logarithm of odds 
(lod) score (Z):  
)(
)(log)( 10 linkagenoL
linkageLZ =θ .
For unlinked loci, ? is expected to equal 0.5. The most likely distance between two 
loci is the recombination fraction at which the lod score peaks. For monogenic 
disorders, a lod score of 3.0 corresponds to a p-value of 0.001 and is considered 
significant evidence of linkage, whereas a lod score of -2.0 indicates significant 
evidence of exclusion of linkage (Ott 1991). 
In parametric analyses, also called model-based methods, three parameters need to 
be estimated prior to any analysis: mode of inheritance, frequency of the disease 
gene in the population and the penetrance of the disease gene. Parametric linkage 
analyses have been successfully used in mapping genes for monogenic diseases. 
However, estimation of the necessary parameters for common complex diseases can 
be difficult. Errors in estimating the parameters will hamper the possibilities to 
detect true signals (Clerget-Darpoux et al. 1986). 
The major advantage of non-parametric analysis or allele-sharing methods is that 
they are not dependent on the estimates needed for the parametric linkage analysis. 
Instead, these methods are based on allele sharing between affected siblings. Under 
random Mendelian segregation, sibling pairs can share 0, 1 or 2 copies of alleles at 
any locus with a distribution of 25%, 50% and 25%, respectively. The distribution in 
the allele sharing can be monitored using a chi-squared test. Excess allele sharing 
between affected siblings suggests an involvement of the chromosomal region in 
disease susceptibility. Any two copies of the allele are called identical by state (IBS). 
If the shared allele is known to be inherited from the common ancestor, the allele is 
called identical by descent (IBD). Unfortunately, in late-onset diseases the parental 
information of the affected siblings is often not available, making the IBD estimation 
difficult. Therefore, a large number of affected siblings is often needed for a 
powerful affected sibpair analysis. 
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Quantitative trait locus (QTL) analysis can be performed in order to avoid the arbitrary 
cut-off points necessary to defining affected and non-affected individuals for 
continuous variables such as BMI or plasma glucose levels. The QTL analysis is based 
on the assumption that phenotypic similarity between related individuals is correlated 
with alleles shared at the locus determining the trait. It has been suggested that QTL 
analysis will better utilize full information in continuous traits. Ideally, study samples 
for QTL analysis are not collected to bias towards either end of the continuum of the 
variable, but instead represent the wide variation present in the general population. For 
the most part, two methods have been used in the QTL analysis; Haseman-Elston 
regression (Haseman and Elston 1972) and variance component analysis (Amos 1994; 
Almasy and Blangero 1998; Blangero et al. 2001). The advantage of the variance 
component methods is that they can include covariates, gene-environment interactions 
and other confounding factors within the model. 
3.3.3 Association analysis 
In genetic association analysis, the allele or genotype frequencies are compared 
between a group of affected individuals and a control group. Two types of settings 
for an association study are usually designed: case-control studies and family-based 
association studies. In classical case-control studies, a sample of unrelated affected 
individuals and a sample of well-matched unrelated controls are studied. The case-
control study designs have been criticized for their potential spurious association due 
to population stratification. Population stratification refers to the existence of 
subgroups in the sample, for instance, the mixing of two or more ethnicities may 
lead to false positive findings (Schulze and McMahon 2002). In addition relatively 
large sample sizes are required to detect significant difference. 
To circumvent the problem of selecting controls, family-based association studies 
were developed. In the Haplotype Relative Risk approach, the alleles transmitted to 
affected offspring are designated as case alleles and the “internal” control group is 
derived from the alleles that are not transmitted from the parents (Falk and 
Rubinstein 1987; Terwilliger and Ott 1992). The transmission/disequilibrium test 
(TDT) also utilizes the “internal” control group, but by extracting data only from 
heterozygous parents (Terwilliger and Ott 1992; Spielman et al. 1993). In the late-
onset disease, a difficulty for these types of analyses arises when the parents of the 
affected individuals are not available. The sib-TDT has been developed to avoid the 
problem of missing parental information. The sib-TDT utilizes information from 
unaffected siblings instead of parents (Boehnke and Langefeld 1998). The original 
TDT has also been extended to accommodate multiple loci, extended pedigrees and 
quantitative traits (Schulze and McMahon 2002).  
Previously, association studies have predominantly been applied to candidate gene 
studies or fine mapping of a linked region. Advanced genotyping technologies and 
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data from the HapMap project are making the genome-wide association analyses 
using dense single nucleotide polymorphism (SNP) maps both affordable and 
feasible. The genome-wide association analyses may be efficient in detecting the 
effects of the common variants with modest effects (Risch and Merikangas 1996). 
However, at the moment genome-wide association analyses are facing a number of 
challenges, including issues of multiple testing, SNP selection, as well as selection 
of the study sample (Risch and Merikangas 1996).
3.4 Linkage disequilibrium, founder populations and mixed 
populations
When alleles of two loci are inherited together with a higher incidence than expected 
by chance, they are in linkage disequilibrium (LD). There are two different and 
frequently used metrics to measure LD; D’ and r2 (Zondervan and Cardon 2004). 
They are both related to the deviation of haplotype frequency in the equilibrium state 
(D). r2 is a measure of correlation between a pair of variables, and it is of particular 
importance in genetic mapping as it is inversely related to the required sample size 
in association analysis (Wang et al. 2005). 
LD is the feature that makes it possible to detect linkage or association between a 
genetic marker and a disease without genotyping the actual causative marker. Small, 
isolated founder populations have turned out to be beneficial in isolating genes for 
rare Mendelian disorders due to the reduced genetic heterogeneity in these 
populations (Peltonen et al. 1999). Fewer disease alleles exist in founder 
populations, and the shared haplotypes around the disease mutations are usually 
extended. As a result, the disease causing mutation in affected individuals may be in 
complete LD with another variant. However, the mutation usually leads to such 
dramatic changes in the gene function that it is possible to pinpoint the actual 
mutation among the harmless polymorphisms by performing functional studies. 
The founder populations may also exhibit beneficial features for isolating genes for 
complex disorders, although, the situation may be more complicated (Peltonen et al. 
2000). In rare monogenic disorders just one or few founders usually introduced the 
disease allele into the population and, thus, the LD around the mutation is extended. 
The common alleles may have entered the gene pool so many times that the length 
of the shared haplotype around the disease alleles may be nearly indistinguishable 
from the more mixed populations (Kruglyak 1999; Shifman et al. 2003; Hirschhorn 
and Daly 2005). However, there is a potential advantage when studying complex 
diseases in isolated populations and it is the similarity in environmental factors and 
life style that people share (Peltonen et al. 2000). 
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LD that is beneficial in the initial identification of the chromosome region linked or 
associated with a complex disease, may become a problem when defining the actual 
causative variant. Causative variants for complex disorders are expected to result in 
less dramatic changes in gene function. Unfortunately, the tools today are often not 
efficient enough to separate the causative variant(s) from the harmless ones in LD 
using functional studies. Overall, data suggest that several isolated populations have 
modestly extended general LD around common alleles (Kaessmann et al. 2002; 
Hirschhorn and Daly 2005). For this reason it may be optimal to use isolated founder 
populations in the initial studies to define the chromosomal region carrying a gene 
predisposing to the disease. To further restrict the associated region and to reveal the 
causative variant, it may be helpful to study more mixed populations. This was 
demonstrated in the positional cloning of the gene predisposing to FCHL on 
chromosome 1q21-23 (Pajukanta et al. 2004). The LD extended to 46 kb in the 
region associated with the disease in Finns. A subsequent study in the more mixed 
Mexican population restricted the region significantly to 14 kb (Huertas-Vazquez et 
al. 2005). 
3.5 HapMap project and haplotype blocks 
Starting in October 2002 the International HapMap project set a goal of producing 
the "next-generation" map of the human genome to facilitate and accelerate the 
discovery of genes related to common complex disorders (The International 
HapMap Consortium 2003). The aim was to provide a limited number of tag-single 
nucleotide polymorphisms (tag-SNPs) for genotyping, in order to cover most of the 
variation in genome without genotyping redundant SNPs. Within three years the 
HapMap project was to provide a SNP and haplotype map of the human genome at 
an extraordinary level of precision. As realized earlier, recombinations in the 
genome do not happen evenly, but instead occur more in so-called recombination 
hot-spots, resulting in “blocks” across the genome (Daly et al. 2001; Gabriel et al. 
2002). Within one block there is little evidence of historical recombination. SNPs 
within a block are in considerable LD and, thus, to obtain maximal information of 
the genetic variation, it is not necessary to genotype all the SNPs in the block. The 
idea of the haplotype blocks and the way in which the HapMap project is expected to 
facilitate the identification of disease genes is presented in figure 6a and b. 
Unlike the original HGP, the HapMap project has faced a lot of criticism regarding 
the usefulness of the information provided by the project, taking into account the 
fact that some genomic regions fit better to the block theory than others (Wall and 
Pritchard 2003b; Wall and Pritchard 2003a). This may imply that usefulness of the 
haplotype block method will be uneven throughout the genome (Weiss and 
Terwilliger 2000; Couzin 2002). By now, there are already some interesting new 
gene discoveries, the identification of which considerably relied on HapMap data 
and on haplotype block structure around the associated region for instance the 
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identification of the complement factor H gene predisposing to macular degenaration 
(Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005). 
DIRECT ASSOCIATION INDIRECT ASSOCIATION
a)
HAPLOTYPE 
BLOCKS
BLOCK 3BLOCK 2BLOCK 1
CHROMOSOMES 
IN POPULATION
b)
Figure 6. The idea behind the HapMap project lies in the linkage disequilibrium (LD) 
between nearby single nucleotide polymorphisms (SNPs) and in the blocks (haplotype 
blocks) that these SNPs cluster in. An increased amount of LD and a reduced amount of 
historical recombination can be seen between the SNPs in the haplotype blocks. To 
identify the SNP causing the disease of interest, the SNP itself does not necessarily need 
to be genotyped (direct association). Instead, the SNP in LD with the causative one may 
give a signal of association (indirect association) (a). The knowledge of the haplotype 
blocks across the genome will help choose SNPs for genotyping, in order to get a 
maximum amount of information of the variation between individuals with minimal 
amount of genotyping (b). Modified from Hirschhorn and Daly (2005) and Cardon and 
Abecasis (2003). 
3.6 Expression studies 
The gene expression is the major determinant of the phenotype and function of a 
living organism. The profile of expressed genes in a particular cell is highly dynamic 
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and changes rapidly in response to cellular events and external stimuli. Methods 
have been available to measure the gene expression of a limited number of genes at a 
time. Recently, DNA microarray technology has provided a tool to monitor the 
expression pattern of a whole genome simultaneously on a single chip (Lockhart and 
Winzeler 2000). In this process total RNA from a particular tissue sample is 
extracted, reverse transcribed and hybridized on a slide containing oligonucleotides 
corresponding to thousands of different genes. Using microarray technology it is 
possible to determine a set of genes expressed or turned off together. Consequently, 
the technique should allow identification of the genes that are differentially 
expressed in healthy and diseased individuals and, thus, to get a clue of the pathways 
important in the disease process. 
3.7 Comparative genomics 
After completion of the enormous HGP, genomic sequences of many other 
organisms have been completed and released. By the end of September 2005 
complete genome sequences of altogether 283 organisms were publicly available, 
including 3 animals in addition to human, 2 plants, 9 fungi, 5 protists and 263 
prokaryotes. In addition to these complete sequences, draft sequences of many other 
mammals are also available such as the draft sequences of chimpanzee, rat, dog and 
cow (http://www.ncbi.nlm.nih.gov/genomes/static/gpstat.html).
It is apparent that exonic regions of the genes are highly conserved between different 
species. In addition to exons, certain intronic and intergenic sequences harbor 
regions that are highly conserved between species. These conserved regions are 
likely to contain important regulatory regions. Comparing sequences of co-regulated 
genes within species may also lead to the detection of conserved regions that carry a 
binding site for a transcription factor or motifs, i.e., clusters of binding sites for 
transcription factors. Although regulatory regions probably constitute only a small 
proportion of all the non-coding sequences, they still determine the level, location 
and chronology of gene expression (Pennacchio and Rubin 2001). 
A number of transcription factor binding sites have been described in the literature. 
Great effort has been made to collect these empirically tested transcription factors 
and their binding sites to a single catalogue, for example TRANSFAC (Wingender 
1988). This information can be used to search for new binding sites of previously 
known transcription factors. The difficulty in the identification of the new sites lies 
in the nature of the transcription factor binding sites; they are typically short 
sequences that carry a small invariant core sequence (4-6 bases) surrounded by a 
variable number of degenerate nucleotides. Full control of the gene expression is 
considered to involve multiple transcription factors, including both enhancers and 
silencers that together coordinate the activity of the gene. 
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MicroRNAs are an interesting genomic feature of gene regulation that was recently 
identified (Ambros 2004; Ying and Lin 2004). They are short fragments, 
approximately 22 nucleotides, encoded by microRNA genes and transcribed to 
RNA, but not translated to protein. MicroRNAs regulate gene expression by binding 
to the untranslated regions (UTR) of the messenger RNAs and, consequently, 
promote their degradation. To identify typical microRNA binding sites, Xie et al. 
(2005) compared UTRs of all the known human and mouse genes. They found 
multiple conserved sequences with strong directional bias to forward strand and to 8-
base length (Xie et al. 2005). This could be reminiscent of a feature of mature 
microRNAs that tend to start with a U base followed by a complementary sequence 
of seven bases, suggesting that most of the identified sequences actually could 
represent microRNA binding sites. 
4 GENETIC VARIATIONS ASSOCIATED WITH 
OBESITY
4.1 The thrifty gene hypothesis 
The ”thrifty gene” hypothesis was initially introduced by James Neel in 1962 as an 
attempt to explain the increase in T2DM prevalence (Neel 1962). He suggested that 
genes or genotypes responsible for improved energy storage during famine and 
starvation provided a survival advantage at a time when humans were hunter-
gatherers, and there have been periods of time when the food supply was plentiful 
followed by periods of famine. All food in the stone-age was obtained via extensive 
physical activity. Thus, the lives of our ancestors alternated between shortage and 
abundance, the latter possibly occurring after successful hunting tending to lead to 
reduced physical activity. Excessive energy consumed during this period was stored 
as TGs in adipose tissue (and glycogen in muscles) referred as thrifty storage. When 
this was followed by decreased amounts of food available with possible famine, 
considerable physical activity was needed to provide food again. Individuals with 
maximal energy storing capabilities during time of abundance, combined with their 
economical usage of the stored energy during famine, were probably the most 
capable of surviving the physical rigors of life. Genes or genetic variations 
enhancing these features were restored in the human genome during the evolution. 
Dramatic changes have occurred in the process of food supply within the last 
thousands of years, which is still a short period in evolutionary terms. Nowadays 
food supply is constant and plentiful, obtainable with minimal physical effort, 
consequently creating a so-called “obesogenic” environment. Most of the job 
descriptions of people in Western societies do not include physical labor, as neither 
do leisure time activities. Therefore, the body of the human being designed to 
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function in the cycles of abundance and shortage have stalled to the abundance step 
prepared to take on the next shortage. When the shortage or extensive physical 
activity never arrives, the properties of efficient energy storage become detrimental, 
predisposing to diseases typical to Western societies, such as overweight, obesity 
and T2DM. Thus, genes previously beneficial are now causing diseases. 
In accordance with the thrifty gene hypothesis, it has been suggested that excess fat 
should not be considered as a disease, i.e., a biological abnormality of an individual, 
but instead as a collective adaptation to the pathological pressure of the environment 
to eat too much and exercise too little (Bell 2005). 
4.2 Genetic epidemiology of obesity and related metabolic 
disorders
Obesity aggregates in families, but the pattern of inheritance does not in most cases 
follow any Mendelian segregation. This suggests a complex mode of inheritance, 
and the proportion of obesity due to genes is somewhat difficult to predict. To 
quantify the familial aggregation, the recurrence risk ?R can be estimated (Risch 
1990a). ?R is the disease risk for a relative of an affected person divided by the 
disease risk in the general population. The ?R value does not directly reflect the 
genetic proportion, since obesity may aggregate in families due to shared genes or 
shared environment. If ?R varies according to the degree of genetic relatedness, 
being larger for closer relatives than for more distant relatives (for example 
monozygotic twins versus dizygotic twins and other first degree relatives, or first 
degree relatives versus second degree relatives), it suggests that there are genetic 
components behind the disease (Risch 1990b; Risch 1990a). The recurrence risk for 
siblings (?S) is often used and it is obtained by dividing the risk ratio for siblings by 
the risk in the general population. Heritability (h2) refers to the actual genetic 
proportion of the disease risk and can be derived from ?R values obtained from 
different kinds of relatives. In a broad sense, heritability can be defined as the 
proportion of the total phenotypic variability VP (=variance due to additive genetic 
effects VA, dominant genetic effects VD and environmental effects VE) due to genetic 
effect VG (= additive and dominant effects). In a narrow sense, heritability is the 
proportion of the total phenotypic variability VP due to the additive genetic effect VA.
For obesity, ?R has been calculated for different kinds of relatives using varying 
population percentiles or BMI cut-offs (Allison et al. 1996a; Lee et al. 1997). The 
risk for obesity (defined as 90th BMI percentile or BMI ? 30 kg/m2) was two to three 
times higher for a person with family history of obesity. The risk increased with the 
severity of obesity, with estimates between ?R of 3-6 for the 95th percentile cut-off 
point or for BMI ? 40 kg/m2.
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Heritability values have been estimated from twin, family and adoption studies, the 
estimates varying from 5% to as high as 90% (Loos and Bouchard 2003). Large 
variation in the heritability estimates may partly be explained by the study design 
and by the kinds of relatives upon which the results are based. Studies on 
monozygotic and dizygotic twins or monozygotic twins reared apart give the highest 
heritability estimates, of the order of 70% (Stunkard et al. 1990; Allison et al. 1996b; 
Maes et al. 1997). Adoption studies suggest the lowest heritability with the values 
clustering around 30% (Stunkard et al. 1986; Sorensen et al. 1992a; Sorensen et al. 
1992b; Vogler et al. 1995). Results from the family studies are intermediate between 
the twin and adoption studies (Rice et al. 1999). Certain diseases and traits that co-
occur with obesity also show high heritability (table 4). Twin studies also suggest a 
considerable genetic component to eating behavior (Tholin et al. 2005). 
Table 4. Heritability estimates and population prevalence of different traits related to 
obesity.  
Trait Population 
prevalence
Heritability
Obesity 30% 30-70 (Loos and Bouchard 2003) 
T2DM 5-10% 40-80 (Permutt et al. 2005) 
Metabolic syndrome 7-43% 24-61 (McQueen et al. 2003; Eckel 
et al. 2005; Lin et al. 2005) 
TG levels Quantitative trait 40-80 (Lander et al. 2004) 
TC levels Quantitative trait 40-60 (Lander et al. 2004) 
HDL-C levels Quantitative trait 45-75 (Lander et al. 2004) 
Leptin levels Quantitative trait 40-60 (Comuzzie et al. 1997; Rotimi 
et al. 1999) 
Eating behavior Quantitative trait 45-60 (Tholin et al. 2005) 
* Abbreviations: high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), 
triglyceride (TG), type 2 diabetes mellitus (T2DM) 
Gene-diet and gene-environment interactions have been suggested in the etiology of 
obesity. Obesity and T2DM are very common among Pima Indians living in United 
States, and they provide an example of the gene-environment interactions (Ravussin 
et al. 1994). Pima Indians living in a remote mountain area in Mexico have lower 
prevalence of obesity and T2DM than those living in more obesogenic areas in the 
United States. A gene-diet interaction has been observed in experimental studies 
performed on monozygotic twins (Bouchard et al. 1990; Hainer et al. 2000). These 
studies show that monozygotic twin pairs have less variation in response to positive 
or negative energy balance compared to the variation between twin pairs. 
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4.3 Genes associated with human obesity and related metabolic traits 
Numerous studies using both candidate gene and genome-wide approaches have 
attempted to identify genes predisposing to obesity. The latest Human Obesity Gene 
Map published in March 2005 was the 11th in a series of reviews collecting and 
reporting the literature published on genes related to obesity (Perusse et al. 2005). 
The findings on obesity genes so far provide support for both the CVCD hypothesis 
and for the classical heterogeneity model. 
4.3.1 Monogenic forms of obesity 
Table 5 shows the genes identified so far harboring variants that either segregate 
with obesity in families, or the variants are only found in obese individuals, or the 
variants have been causally linked to obesity (Perusse et al. 2005). However, obesity 
is seldom caused by a single gene defect in general population (Bell et al. 2005). 
Table 5. Genes causing monogenic forms of obesity in humans.
Gene Reference 
Leptin (LEP) (Montague et al. 1997; Strobel 
et al. 1998; Ozata et al. 1999) 
Leptin receptor (LEPR) (Clement et al. 1998) 
Pro-opiomelanocortin (POMC) (Krude et al. 1998; Challis et 
al. 2002) 
Prohormone convertase-1 (PC1) = Ectonucleotide 
pyrophosphatase/phosphodiesterase 1  (ENPP1) 
(Jackson et al. 1997; Jackson 
et al. 2003) 
Melanin-concentrating hormone receptor 1 
(MCHR1) = G protein-coupled receptor 24 (GPR24) 
(Gibson et al. 2004) 
Melanocortin-3 receptor (MC3R) (Lee et al. 2002) 
Melacortin-4 receptor (MC4R) (Vaisse et al. 1998; Yeo et al. 
1998; Perusse et al. 2005) 
Corticotropin-releasing hormone receptor-1 
(CRHR1) 
(Challis et al. 2004) 
Corticotropin-releasing hormone receptor -2 
(CRHR2) 
(Challis et al. 2004) 
bHLH-PAS transcription factor (SIM1) (Holder et al. 2000; Faivre et 
al. 2002) 
The cloning of the ob gene in the mouse and its human homologue, Leptin (Zhang et 
al. 1994) provided the first example of a causal relationship between a mutation and 
obesity. Two different mutations disrupting the structure of the Leptin gene have so 
far been identified in 6 morbidly obese children (Montague et al. 1997; Strobel et al. 
1998; Ozata et al. 1999). When these children were treated with the recombinant 
leptin protein, their weight was dramatically reduced (Farooqi et al. 1999). 
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Unfortunately, the lack of or reduced amount of leptin protein in obese individuals does 
not seem to be a common cause of obesity. Rather, obese individuals often have elevated 
serum leptin levels and leptin resistance (Considine et al. 1996; Ren 2004). 
In addition to genetic defects mostly affecting body weight, numerous syndromes 
featuring obesity as one of the symptoms have been mapped to certain chromosomal 
loci, and for some of these the underlying gene has been identified (Perusse et al. 
2005). Of these syndromes, the Prader-Willi syndrome is the most common one 
affecting every 16,000-25,000 newborn a year (Burd et al. 1990; Butler 1990). The 
Prader-Willi syndrome is an imprinting disorder that is usually caused by a deletion 
of a paternally inherited chromosome 15q region. In addition to defects in the 
nuclear genome, mutations in the mitochondrial genome have been associated with 
obesity-related disorders (Wilson et al. 2004). 
Of these rare forms of obesity, mutations in MC4R are by far the most common, and 
their prevalence has been estimated to be as high as 4% among obese children 
(Farooqi et al. 2000; Vaisse et al. 2000; Perusse et al. 2005). The degree of obesity 
in individuals carrying an MC4R mutation varies and these individuals are usually 
also taller. A recent meta-analysis suggests that the common allele of the val103ile 
variant in the coding region of the MC4R is associated with obesity, whereas the rare 
allele (ile103) with a frequency of 4% was more common in lean individuals (Geller 
et al. 2004). The ile103 allele was also associated with lower BMI in a large 
population-based sample (Heid et al. 2005). 
4.3.2 Common forms of obesity 
Multiple genome-wide scans have been performed for obesity and traits related to 
body composition (Perusse et al. 2005). Typically in complex disorders, the first 
identification of a region linked to the disease does not automatically lead to 
replication in a follow-up study performed in another study sample. However, 
evidence of linkage (lod score > 3.0 or p < 0.001) for obesity and traits related to 
body composition has been identified in several studies for certain chromosome 
regions, see figure 7. 
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REGION LINKED TO 
OBESITY-RELATED TRAIT
Figure 7. The chromosomal regions showing evidence of linkage (lod score >  3.0 or p < 
0.001) to obesity, BMI, body composition, waist circumference, leptin levels and 
adiponectin levels in genome-wide scans. References: (van der Kallen et al. 2000) chr 1 
and 10; (Ng et al. 2004) chr 1; (Comuzzie et al. 1997) and (Deng et al. 2002) and (Chen 
et al. 2005a) chr 2; (Moslehi et al. 2003) chr 2, 3 and 11; (Palmer et al. 2003) chr 2 and 
12; (Kissebah et al. 2000) chr 3 and 17; (Watanabe et al. 2000) chr 3 and 13; (Wu et al. 
2002) chr 3; (Stone et al. 2002) and (Arya et al. 2004) chr 4; (Comuzzie et al. 2001) chr 
5 and 14; (Gorlova et al. 2003) chr 5, 16 and 20; (Fox et al. 2004) and (Meyre et al. 
2004) chr 6; (Borecki et al. 1994) chr 7 and 20; (Feitosa et al. 2002) chr 7 and 13; 
(Adeyemo et al. 2003) chr 7 and 11; (Platte et al. 2003) chr 7; (Hager et al. 1998) chr 
10; (Hanson et al. 1998) chr 11;  (Li et al. 2004) chr 12 and 21; (Chagnon et al. 2001) 
chr 14 and 19; (Chagnon et al. 2000) chr 15 and 18; (Geller et al. 2003) chr 16; (Bell et 
al. 2004) chr 17 and 19; (Lee et al. 1999) and (Hunt et al. 2001) chr 20; (Martin et al. 
2002) chr 22; (Ohman et al. 2000) chr X. 
Multiple genes have been associated with common forms of obesity, although only 
few of them have been replicated in other studies (Perusse et al. 2005). This can be 
explained by several circumstances including the small risk that the disease-
associated variant presents, small sample sizes of the studies, and LD between the 
actual causative variants and the variants tested in the study. The gene-gene or gene-
environment interactions and phenotypic heterogeneity may also complicate the 
analysis if the study populations have different haplotype backgrounds or different 
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environmental exposures. Despite these difficulties, the initial associations of some 
genes with obesity or related phenotypes have been replicated. The genes for which 
at least five different studies found association with obesity or obesity related 
phenotypes include Adiponectin, Adrenergic, beta-2- and beta-3- receptors (ADRB2 
and ADRB3), Guanine nucleotide binding protein (G protein), beta polypeptide 3 
(GNB3), Interleukin 6 (interferon, beta 2) (IL6), Insulin, Leptin (LEP), Leptin 
receptor (LEPR), Lamin A/C (LIPE), Nuclear receptor subfamily 3, group C, 
member 1 (NR3C1), PPARG, Tumor necrosis factor TNF superfamily, member 2 
(TNF), as well as Uncoupling protein proteins 1, 2 and 3 (mitochondrial, proton 
carrier) (UCP1, UCP2 and UCP3) (Perusse et al. 2005).
Recently marked progress has been made in the identification of obesity-
predisposing genes using genome-wide linkage and subsequent fine mapping studies 
(Boutin et al. 2003; Bell et al. 2005; Meyre et al. 2005a). The benefit of the 
positional cloning strategy is that it does not rely on any pre-existing knowledge of 
the genes that underlie the investigated trait. Particularly, for conditions such as 
obesity this may be useful since there is as yet limited information available, for 
instance regarding the appetite regulation. The first candidate gene for obesity 
identified through the genome wide approach was Glutamate decarboxylase 1 
(GAD2) on chromosome 10p12 (Boutin et al. 2003). It encodes the glutamic acid 
decarboxylase enzyme GAD65 and may be connected to obesity via the 
hypothalamic regulation of food intake. GAD2 is involved in the formation of the ?-
aminobutyric acid (GABA) from the glutamic acid. GABA functions together with 
neuropeptide Y in the paraventricular nucleus to increase food intake. Later, GAD2
polymorphisms were associated with childhood obesity, birth weight and binge 
eating (Meyre et al. 2005b). However, a recent replication study involving German, 
American and Canadian populations did not confirm the association with obesity 
(Swarbrick et al. 2005). 
Another interesting example is the Ectonucleotide pyrophosphatase/ 
phosphodiesterase 1 (ENPP1) gene in chromosome 6q22-23. This 6q22-23 region 
has been linked to obesity (Atwood et al. 2002; Meyre et al. 2004), BMI (Atwood et 
al. 2002), insulin secretion (Duggirala et al. 2001; Abney et al. 2002) and T2DM 
(Ehm et al. 2000; Ghosh et al. 2000; Demenais et al. 2003; Xiang et al. 2004). 
Recently, variants in ENPP1 were identified to be associated with obesity and 
T2DM (Meyre et al. 2005a). ENPP1 encodes a prohormone convertase-1 enzyme 
which inhibits the insulin receptor kinase activity and subsequent cellular signaling 
of insulin (Maddux et al. 1995; Maddux and Goldfine 2000). ENPP1 is also 
involved in the post-translational processing of the propeptide that is encoded by the 
POMC gene. Splicing of the propeptide produces adrenocorticotropin, ?-lipotropin, 
?-, ?- and ?-melanocyte-stimulating hormones. 
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4.3.3 Genes conferring susceptibility to obesity-related metabolic traits 
In addition to genes primarily identified to cause or increase susceptibility to obesity, 
gene variations have been identified that contribute to variation in TG, HDL-C and 
TC levels or predispose to diabetes. Examples of such genes are given in table 6. 
Table 6. Examples of genes with common variations associated with obesity-related 
metabolic traits. 
Gene Chromosome Trait Population
ATP-binding cassette, 
sub-family A (ABC1), 
member 1 (ABCA1) 
9q31 HDL-C (Cohen et al. 2004; Frikke-
Schmidt et al. 2004) 
Upstream transcription 
factor 1 (USF1) 
1q21 TG 
FCHL
(Pajukanta et al. 2004; 
Huertas-Vazquez et al. 
2005) 
Lipoprotein lipase (LPL) 8p22 TG (Hokanson 1997; Wittrup et 
al. 1999) 
Apolipoprotein E (APOE) 19q13.2 TC 
TG
(Zannis and Breslow 1981; 
Dallongeville et al. 1992) 
APOC3/A4/A5 gene 
cluster
11q23 TG (Pennacchio et al. 2001; 
Talmud et al. 2002) 
Peroxisome proliferative 
activated receptor-?
(PPARG) 
3p25 T2DM (Deeb et al. 1998; Altshuler 
et al. 2000) 
Calpain 10 (CAPN10) 2q37.3 T2DM (Horikawa et al. 2000; 
Weedon et al. 2003) 
Hepatocyte nuclear factor 
4-? (HNF4A) 
20q13 T2DM (Love-Gregory et al. 2004; 
Silander et al. 2004) 
* Abbreviations: familial combined hyperlipidemia (FCHL), high density lipoprotein 
cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG), type 2 diabetes mellitus 
(T2DM) 
4.4 Animal models of obesity and related traits 
Numerous naturally occurring monogenic and polygenic obese mouse strains have 
been identified that manifest increases or decreases in adiposity, as well as show 
features related to body weight regulation, such as eating behavior or energy 
metabolism (Robinson et al. 2000; Perusse et al. 2005). Transgenic and knock-out 
animal models of obesity have also been created using recombinant DNA 
technology. Animal studies have provided a large amount of valuable information 
regarding the physiology and molecular mechanisms of body weight regulation. 
Some of them have lead to the identification of mutations in the corresponding 
human homologue or in the genes acting on the same pathway, for example genes in 
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the leptin-melanocortin pathway (O'Rahilly et al. 2003), see table 7. However, 
identification of a mutated gene in an animal model does not automatically lead to 
detection of a defect in the human homologue, which may reflect the heterogeneous 
phenotype and genetic heterogeneity in humans and also reflect the difficulties of 
performing studies that are as tightly controlled as animal studies. 
Table 7. Genes in the leptin-melanocortin pathway that were identified in spontaneous 
mouse strains or studied in recombinant mice models, and the related human gene 
harbouring obesity-associated variations. 
Mouse strain Mouse gene Human gene
ob/ob Leptin (Lep) Leptin (LEP)
db/db Leptin receptor (Lepr) Leptin receptor (LEPR)
fat/fat Carboxypeptidase E (Cpe) Prohormone convertase-1 (PC-1) 
agouti Agouti Signaling Protein (ASP) Agouti-related protein (AGRP)
mahogany Attractin (Atrn) Attractin (ATRN)
MC4R-KO Melanocortin-4 receptor (Mc4r) Melanocortin-4 receptor (MC4R)
POMC-KO Pro-opiomelanocortin (Pomc) Pro-opiomelanocortin (POMC)
* knock-out (KO) 
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AIMS OF THE PRESENT STUDY 
The aim of the present study was to investigate the genetic background of obesity 
and related metabolic disorders by addressing the following specific aims: 
• To investigate the prevalence of monogenic forms of obesity caused by 
mutations in the Melanocortin-4 receptor gene (MC4R) on chromosome 
18q22) and Pro-opiomelanocortin gene (POMC) on chromosome 2p23.3, 
and to test the common variants in these genes for association with obesity 
related traits 
• To examine in humans the possible role of the Lipin 1 gene (LPIN1) on 
chromosome 2p25.1 previously identified for lipodystrophy, 
hypertriglyceridemia and insulin resistance in mice 
• To fine map six chromosomal regions: 2q31, 8q23, 10q11, 16q24.1-24.2, 
20q13.11 and Xq24 previously linked to obesity, CHD, FCHL, high serum 
TG and low HDL-C levels. 
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MATERIALS AND METHODS 
Materials or methods Original publication 
Study samples 
      Swedish cases and controls 
      Obesity families 
      Finnish cases and controls 
      Low HDL-C families 
      FCHL families 
I, III 
III
II, III 
II, IV 
II, IV 
DNA isolation I-IV 
Single-strand conformation polymorphism (SSCP) 
analyses 
I
SNP genotyping I-III 
Sequencing I, III 
Microsatellite marker genotyping III, IV 
Fat biopsies and RNA extraction II 
Expression array analysis of adipose tissue II 
Statistical analyses 
      Regression analysis 
      Chi-squared tests 
      Affected sibpair analyses 
      LD estimation 
      Family based association tests 
      Analysis of Covariance 
      QTL analyses 
I
I-III
III
II, III 
II
II
IV
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1 STUDY SUBJECTS 
Five different study samples from the following sources were included in this study. 
The Swedish obese cases and lean controls were collected at the Obesity Clinic in 
Malmö, Sweden (study I and III). The Finnish obese families were collected at the 
Helsinki University Central Hospital, the Tampere University Hospital, and the 
Peijas Hospital in Vantaa, as well as from the participants of the Finnish Twin 
Cohort (study III) (Kaprio 1994). The Finnish obese cases and lean controls were 
recruited from the Helsinki University Central Hospital, the National FINRISK97 
cohort (Vartiainen et al. 2000) and the Botnia study (Parker et al. 2001; Lindgren et 
al. 2002) (study II and III). The low HDL-C families and FCHL families were 
collected at the Helsinki and Turku University Central Hospitals as part of the 
EUFAM study (study II and IV). Each study subject provided a written informed 
consent prior to participating in the study. All samples were collected in accordance 
with the Helsinki declaration, and the ethics committees of the participating centers 
approved the study design. 
1.1 Family samples 
1.1.1 Obese families 
The family sample for obesity (BMI ? 30 kg/m2) included 218 obese sibpairs from 
184 Finnish nuclear families. Of these sibpairs, 54 were recruited through a proband 
attending the weight-reduction program at the Helsinki University Central Hospital. 
These families had at least one additional obese sibling with a BMI ? 32 kg/m2.
Another 46 sibpairs from 34 families were ascertained through the Finnish Twin 
Cohort. These sibpairs were dizygotic twins, with their obese siblings all having a 
BMI ? 32 kg/m2. In addition, 93 sibpairs from 79 families were collected in the 
weight-reduction groups at the Helsinki University Central Hospital, the Tampere 
University Hospital, and the Peijas Hospital, as well as screened from the 
participants of the Finnish Twin Cohort (Kaprio 1994). The probands from the 
weight-reduction groups enrolling in the study had a sibling with a BMI ? 30 kg/m2.
Of the dizygotic twins, both twins had a BMI ? 30 kg/m2. We also included 25 
Finnish obese sibpairs (BMI ? 30 kg/m2) from the families ascertained for FCHL or 
low serum HDL-C levels. 
Altogether 467 individuals were genotyped. Of these, 398 individuals had a BMI ?
30 kg/m2 and were coded as affected (157 males / 241 females, age = 50.7 ± 8.4 
years, BMI = 35.8 ± 5.9 kg/m2). In addition, 59 unaffected family members were 
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genotyped to increase the phase information. On average, 2.2 affected members 
were present in these families. 
1.1.2 FCHL and low HDL-C families 
The proband in each FCHL and low HDL-C family was diagnosed for premature 
CHD. In the FCHL families, the proband had also elevated TG and/or TC levels 
according to the Finnish 90th age- and sex-specific population percentile based on 
the population surveys FINRISK and LASERI (Porkka et al. 1994; Vartiainen et al. 
1994; Vartiainen et al. 2000). In addition to the proband, at least two affected family 
members were required in each of the families before any family was included in the 
study. The inclusion and exclusion criteria for the probands are presented in table 8. 
The family members were coded as affected if they had the combined 
hyperlipidemia, i.e., had elevated TG and TC levels or if either of these traits 
exceeded the 90th population percentile level. These criteria follow the original 
diagnostic criteria for FCHL, as suggested by Goldstein et al. (1973).  
Table 8. Diagnostic criteria for the familial combined hyperlipidemia (FCHL) 
probands (Pajukanta et al. 1998; Pajukanta et al. 1999). 
INCLUSION CRITERIA 
Age 30-55 years for males, < 60 years for females 
Premature coronary heart disease (angiographically verified > 50% stenosis in at 
least one coronary artery or survived myocardial infarction) 
TC and/or TGs > age-sex specific Finnish 90th percentiles 
At least one first degree relative affected by FCHL (high TC and/or high TGs)1
EXCLUSION CRITERIA 
Diabetes mellitus, type 1 
Severe renal or hepatic disease 
Hypothyreosis 
Familial hypercholesterolemia2
1If the proband had only one elevated lipid trait, a first-degree relative had to have 
the combined phenotype. 2Familial hypercholesterolemia was excluded by 
determining the low density lipoprotein -receptor status of the proband by the 
lymphocyte culture method (Cuthbert et al. 1986). Abbreviations: familial 
combined hyperlipidemia (FCHL), total cholesterol (TC), triglyceride (TG)
In the low HDL-C families, the proband had premature CHD, as well as HDL-C 
levels below the 10th age and sex-specific population percentile values (Porkka et al. 
1994; Vartiainen et al. 1994; Vartiainen et al. 2000). The inclusion and exclusion 
criteria for the probands are listed in table 9. In addition to the proband, at least two 
members in these families were affected. 
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Table 9. Diagnostic criteria for  the low high density lipoprotein cholesterol 
(HDL-C) probands (Lilja et al. 2002; Soro et al. 2002). 
INCLUSION CRITERIA 
Age 30-60 years 
Premature coronary heart disease (angiographically verified > 50% stenosis at 
least in one coronary artery or survived myocardial infarction*) 
HDL-C < 10th age-sex specific Finnish population percentiles 
At least three accessible first-degree relatives 
At least one first degree relative affected by low HDL-C 
EXCLUSION CRITERIA 
Diabetes mellitus, type 1 diabetes mellitus and type 2 diabetes mellitus 
Body mass index > 30 kg/m2
Severe renal or hepatic disease 
Hypertriglyseridemia (TG > 2.3 mmol/l for both genders) 
Hypercholesterolemia (TC > 6.3 mmol/l for males, > 6.0 mmol/l for females) 
*Following three criteria had to be fulfilled for the myocardial infarction diagnosis: 
(1) typical clinical symptoms, (2) definite electrocardiographic findings, according 
to the Minnesota coding (WHO criteria) (Rose et al. 1982), and (3) elevated levels of 
the creatine-kinase enzyme (CK) and its cardiac isoenzyme, CK-MB. Abbreviations: 
familial combined hyperlipidemia (FCHL), high density lipoprotein cholesterol 
(HDL-C), total cholesterol (TC), triglyceride (TG)
All accessible family members from the FCHL and low HDL-C families were 
included in the study and examined for BMI, serum TG, TC, HDL-C, high density 
lipoprotein cholesterol particles 2 and 3, apolipoprotein A1, apolipoprotein A2, 
LDL-C, apoliporotein B, LDL particle size, insulin levels, blood glucose levels, as 
well as for hepatic and lipoprotein lipase activities. The combined study sample of 
53 FCHL and 39 low HDL-C families comprised 1109 genotyped individuals. 
Because T2DM and obesity were not excluded in the FCHL families, some patients 
also fulfilled the criteria for the metabolic syndrome. The characteristics of the 
pedigrees are shown in table 10. 
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Table 10. Charasteristics of the FCHL and low HDL-C families to show the number 
of generations, number of affected subjects and affected sibpairs for TG, TC, FCHL, 
and HDL-C.   
53 Finnish FCHL 
families 
39 Finnish low 
HDL-C families 
No. of individuals, M/F 431/430 258/276 
No. of probands, M/F 35/18 32/7 
No. of families in each group/Mean no. 
of individuals of which DNA is available 
in each family type:   
 2 generations 3/6 1/6 
 3 generations 42/17 32/13 
 4 generations 7/24 5/20 
 5 generations 1/51 1/33 
No. of affected subjects, M/F; Mean 
no. of affected subjects  in families  
is given in parenthesis:   
 TG > 90th percentile 91/111  (4) 10/39 (1) 
 TC > 90th percentile 110/116 (4) 21/24 (1) 
 FCHL1 132/162 (5) 29/54 (2) 
 HDL-C < 10th percentile 117/120 (4) 95/79 (5) 
No. of affected sibpairs (independent):   
 TG > 90th percentile 66 8 
 TC > 90th percentile 59 4 
 FCHL1 111 12 
 HDL-C < 10th percentile 72 62 
1TG and/or TC > 90th percentile. Abbreviations: M = male; F = female; FCHL= 
familial combined hyperlipidemia; HDL-C = high density lipoprotein cholesterol; 
TG = triglycerides; TC = total cholesterol 
1.2 Case-control study sample for obesity 
For the initial association study (III), one obese male from each of the 184 original 
nuclear families ascertained for obesity was selected when present (n = 117). For the 
replication study (III), an independent study sample was collected in Finland and 
Sweden. The obese individuals were recruited from the Obesity Clinics in Helsinki 
and in Malmö, from the National FINRISK97 cohort in Finland (Vartiainen et al. 
2000), and from the Botnia study (Parker et al. 2001; Lindgren et al. 2002). All the 
obese subjects at the Obesity Clinics in Finland and Sweden had a BMI > 30 kg/m2.
These patients had contacted the obesity clinic on their own initiative and when first 
contacting the clinic, the patients had a BMI > 35 kg/m2. The obese cases selected 
from the National FINRISK97 cohort had a BMI > 35 kg/m2. The obese males 
selected from the Botnia study had a BMI > 30 kg/m2 and at least one additional 
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sibling with a BMI > 30 kg/m2. Altogether 968 lean control subjects with a BMI ?
25 were collected from the same geographical regions as the obese cases. Of these 
lean controls, 514 were males and 195 females from Finland, 73 males and 186 
females from Sweden. The age and BMI distributions of the study sample are 
presented in table 11.
Table 11. Mean age and body mass index (BMI) of the Finnish and Swedish subjects in 
the case-control study sample for obesity.  
 All Finnish Swedish 
 Cases 
(M/F)
Controls
(M/F)
Cases 
(M/F)
Controls
(M/F)
Cases 
(M/F)
Controls
(M/F)
n 837 
(421/416)
968
(587/381)
568
(349/219)
709
(514/195)
269
(72/197)
259
(73/186)
Age
(years) 
48.5 ± 12.3 49.1 ± 11.3 51.5 ± 10.7 52.1 ± 9.6 41.9 ± 12.2 44.8 ± 14.0 
BMI
(kg/m2)
39.8 ± 6.6 23.0 ± 1.4 38.7 ± 6.4 23.4 ± 1.5 41.1 ± 6.9 22.3 ± 1.7 
* Age and BMI values are given as mean ± standard deviation. Abbreviations: M = 
male; F = female
The Swedish obese and lean individuals were included in the study of the POMC
and MC4R genes (I). In the study of the LPIN1 gene (II), the Finnish obese cases and 
lean controls were investigated. 
2 METHODS
2.1 Single-strand conformation polymorphism analyses 
The exonic regions of MC4R and POMC were screened for mutations in overlapping 
PCR fragments using single-strand conformation polymorphism (SSCP). The MC4R
gene was screened for mutations using radioactive SSCP as described in study I. 
When screening POMC, a real time electrophoresis system was applied with 
fluorescently labelled (HEX) primers (Gel Scan 2000, Corbett Research, Sydney, 
Australia). The amplified samples were diluted 1:1 with formamide containing 
0.025% bromophenol blue and heat denatured for 3 min at 90°C. Aliquots (1 μl) of 
the diluted samples were loaded on two 5% polyacrylamide gels (49:1 
acrylamide:polyacrylamide, with or without 2% glycerol). Runs were performed at 
17°C in TBE buffer (71 mM Tris-borate pH 8.3, 1.0 mM EDTA).
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2.2 SNP genotyping 
The SNPs in the genes were primarily chosen in the coding regions and in the genomic 
regions conserved between humans and mice, see figure 8. No HapMap data were 
available for selecting SNPs when this study was conducted. The SNPs in the non-
conserved region (crossed in figure 8) were omitted from the study at this step. The 
SNPs in the conserved regions (circled in figure 8) were chosen to further confirm that 
they were polymorphic by sequencing eight individuals. Eventually, SNPs located in 
the conserved regions, revealing at least one heterozygote within eight individuals and 
not in complete LD among others, were chosen for genotyping in the study sample. 
Figure 8 presents an example of a comparison between genomic sequences of human 
and mouse (gene ± 10 kb) performed using the Pipmaker program. 
•top vertical line = human sequence
•bottom vertical line = mouse sequence
•grey bars = exons
•small vertical ’dots’ = conservation between two species
Figure 8. An example of SNP selection procedure used in the study. A comparison of the 
genomic sequences between human and mouse using Pipmaker program is presented in 
the figure. 
A pyrosequencing technique was applied for the small scale SNP genotyping using 
the PSQ96 instrument and the SNP Reagent kit (Pyrosequencing AB, Uppsala, 
Sweden) in the finemapping stage of the study III. When the sample size exceeded 
400 DNA samples homogenous Mass Extension reaction on the Mass Array System
(Sequenom, San Diego, California, USA) was applied according to the 
manufacturer’s instructions. 
2.3 Sequencing
The sequencing analysis was performed in study I to determine the nucleotide 
variation resulting in abnormal migration patterns in SSCP, and in study III to 
confirm the polymorphicity of the SNPs, as well as to analyze the genomic sequence 
of the Solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14)
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gene. Sequencing was performed using the BigDye Terminator Cycle Sequencing 
protocol (Applied Biosystems Inc.) with minor modifications, and the samples were 
separated with the automated DNA sequencer ABI 377XL (Applied Biosystems 
Inc.). Sequence contigs were assembled through the use of Sequencher software 
(Gene Codes Corp., Ann Arbor, Michigan, USA). To promote sequencing of the last 
four GC-rich fragments 5% dimethylsulfoxide (DMSO) was added to the sequencing 
reaction mixture and the denaturing temperature was increased to 98°C during 
amplification cycles.  
2.4 Microsatellite marker genotyping 
The selection of the markers, as well as the order and distances of the markers, were 
based on the genetic maps of the Celera (http://www.celera.com), the Marshfield 
Comprehensive Human Genetic Map (http://research.marshfieldclinic.org/genetics),
and the Human Genome Browser Gateway (http://www.genome.ucsc.edu). In the 
study III, microsatellite markers were genotyped using the ABI Prism 3700 DNA 
Analyzer and were analyzed with the Genotyper 3.7 software (Applied Biosystems 
Inc., Foster City, California, USA). In the study IV, the genotyping was performed at 
the Finnish Genome Center (Helsinki, Finland). The fluorescence-labeled PCR 
products were pooled into panels and the pooled samples were dialyzed before 
electrophoresis, which was performed on a MegaBace 1,000-capillary 
electrophoresis instrument (Molecular Dynamics). Alleles were defined by using
Genetic Profiler version 1.1 software (Molecular Dynamics). 
2.5 Statistical analyses 
Comparison of allele- and genotype combination frequencies between the two 
groups was performed by the 2 test (studies I-III). The significance of differences 
between clinical characteristics was assessed using regression analysis in the study I. 
The ranks of leptin were used as dependent variable in the regression analysis where 
age, sex and BMI were included as covariates. The BMDP Statistical Software 
version 1.12 (BMDP Statistical Software Inc., Los Angeles, CA, USA) or the NCSS 
Statistical Package (NCSS, Kaysville, Utah, USA) was used in the analysis. 
In the study II, the quantitative trait BMI was tested for association with SNPs using 
a measured genotype approach. Since there were differences in BMI distributions of 
females and males within the obese and lean groups, the measured genotype 
analyses were performed separately in four groups; obese males, obese females, lean 
males and lean females. Because BMI did not follow a normal distribution in any of 
these groups, the nonparametric Kruskal-Wallis test was used to evaluate differences 
in BMI ranks categorized by SNP genotypes. BMI values were corrected for age 
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before ranking the residuals. These analyses were carried out using the SPSS 12.0.1 
software (SPSS Inc., Lead Technologies, Chicago, IL, USA). 
To test for association with obesity with the multilocus genotypes of the two X-
linked SNPs (study III), one overall analysis of males and females of Swedish and 
Finnish origin was performed using the option Genetic Homogeneity of the Mendel 
program (Lange et al. 2001). In this analysis, empiric p-values were calculated by 
permuting the case and control labels within the categories of Swedish males, 
Swedish females, Finnish males, and Finnish females simultaneously, and combining 
the data for each permutation to establish a distribution of possible genotypes for 
cases and controls. 
In the family-based association analysis, preferential transmission of SNPs and their 
haplotypes to quantitative lipid traits in offspring was tested using the FBAT and 
HBAT (family and haplotype based association test) software (Laird et al. 2000). 
Options optimize offset (-o) and haplotype permutation (-p) were used to obtain 
information from the entire families. Permutation was done 100000 times to obtain 
empiric p-values for the haplotype association analyses. Prior to these analyses, BMI, 
TG, glucose and insulin levels, as well as LPL and HL activities were log-transformed 
when necessary and adjusted for age and sex by multiple regression analysis, and the 
residuals were used in the analyses. When analyzing males and females separately the 
regressions to adjust for age were conducted for each sex separately. 
To test the microsatellite markers and SNPs for linkage (study III), nonparametric 
affected sibpair approach was applied using the MAPMAKER/SIBS 2.0 program 
(Terwilliger and Goring 2000). This method of analysis estimates the proportion of 
allele sharing on the X chromosome in three kinds of sibpairs separately: male-male, 
male-female and female-female. The option "all pairs weighed" was chosen to obtain 
information also from families having more than two obese siblings. Haplotypes
were constructed using the GENEHUNTER program, version 1.3, for the male 
sibpairs and for male case and control subjects (Kruglyak et al. 1996). Haplotyping 
of X-chromosome markers in males is unambiguous, since males are hemizygous for 
the X chromosome. 
In the study IV, qualitative analyses were performed using both parametric linkage
and nonparametric affected sibpair analyses. For the parametric linkage analyses, the 
MLINK program of the linkage package (Lathrop et al. 1984) version FASTLINK 
4.1P (Cottingham et al. 1993; Schaffer et al. 1994) was selected. The identical-by-
descent status of affected sibpairs was assessed with the help of the SIBPAIR 
program (Kuokkanen et al. 1996) of the ANALYZE package (Terwilliger and 
Goring 2000). The parametric linkage analyses were performed with dominant and 
recessive modes of inheritance. Gene frequencies of 0.4% and 8%, reflecting an 
estimated population prevalence of 1%, were used for the dominant and recessive 
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modes of inheritance of the HDL-C trait. For TGs, gene frequencies of 0.6% and 
11% were adopted for the dominant and recessive modes of inheritance.  
To investigate the earlier identified regions using quantitative measures by variance 
component methods in extended families, QTL analyses were conducted using 
maximum likelihood-based approaches implemented in the computer program 
SOLAR, version 1.7.4 (Almasy and Blangero 1998). The significance of age, sex, 
and BMI as covariates was tested in our analyses of HDL-C and TGs. Individual TG 
and apoB levels were log transformed to reduce skewness and kurtosis. Data for the 
10q11 region were also analyzed with the QTL program MERLIN (Abecasis et al. 
2002) to compare the results obtained with SOLAR with another QTL-based 
program. A novel QTL association method included in the software package Mendel 
(Lange et al. 2001) was applied in the study IV. 
Pairwise LD between the marker genotypes was assessed using ldmax option in the 
GOLD (graphical overview of linkage disequilibrium) program in the study II and 
using the Genepop v3.1b program, option 2 (http://wbiomed.curtin.edu.au/genepop)
in study III. 
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RESULTS
1 Mutation screening of the POMC and MC4R genes 
In the first part of this study, we estimated the prevalence of obesity caused by 
mutations in the MC4R and POMC genes among morbidly obese Swedish adults (n 
= 102). Secondly, we investigated the association of common polymorphisms in 
POMC with obesity and?or serum leptin levels in morbidly obese or lean individuals 
(n = 118). 
In the MC4R gene, we detected two previously known SNPs in the coding region; 
val103ile (A700G) and ile251leu (A1144C). Both polymorphisms were rare with 
frequencies of 2.0% and 3.9%, respectively, in the obese group. 
Altogether five sequence variations were detected in POMC, all of which have been 
described earlier (Hinney et al. 1998; Echwald et al. 1999; Hixson et al. 1999; 
Delplanque et al. 2000). Of these, two were rare SNPs; C4512T (exon 2) and 
C7726T (exon 3). The more common variants were a 9-bp insertion 
[(AGC)2(GGC)1] at codon 56 (after nucleotide 7677), an A8021G variant in the exon 
3 at codon 188 and a C8246T polymorphism in the 3'-UTR region. The 9-bp 
insertion (ins56) is located in the coding region of the exon 3, and results in three 
additional amino acids in the protein product SerSerCys to the CLIP peptide. The 
A8021G variant leads to an amino acid change Glu188Gly in the ?-lipotropin 
fragment, as depicted in figure 9. 
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Figure 9. Structure of the POMC gene, the peptides encoded by 
it and the variants detected in the study. 
The POMC gene variants ins56, Glu188Gly, C8246T and RsaI were genotyped in all 
study subjects. None of these variants in the POMC gene were associated with 
obesity. However, lean carriers of the C8246T CC-genotype had higher serum leptin 
levels compared to the carriers of the CT or TT genotype (9.7 ± ?6.6 vs. 6.7 ± ?4.4 
μg/l, p = 0.003, p-values for leptin levels adjusted for age, sex and BMI in the 
regression analysis). Females contributed the most to the difference (13.6 ± ?5.8 vs. 
8.5 ± ?4.4 μg/l, p = 0.004), and the difference was even more pronounced among the 
lean female carriers of the C8246T(CC)/RsaI(--or +-) genotype combinations (14.9 ± 
?4.5 vs. 10.8 ± ?5.7 μg/l, p < 0.0005). In contrast, neither the C8246T variant nor the 
C8246T(CC)/RsaI(--or +-) genotype combinations were associated with serum leptin 
levels in the obese subjects (32.4 ± ?12.2 vs. 33.7 ± 11.9 μg/l, p > 0.05 and 32.7 ± 
12.4 vs. 33.4 ± ?11.9 μg/l, p > 0.05). 
To conclude, monogenic forms of obesity due to mutations in POMC or MC4R were 
rare in the Swedish obese patients. Genetic variation in POMC was associated with 
serum leptin levels within the lean individuals, but not in obese. This may emphasize 
the link between an adipose tissue signaling through leptin and the hypothalamic 
endocrine system as represented by POMC.
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2 Cross-species analyses implicating Lipin 1 involvement 
in human glucose metabolism 
Proper function of the Lipin 1 (Lpin1) gene is crucial for normal adipose tissue 
differentiation, as well as for maintaining glucose and lipid homeostasis in mice 
(Reue et al. 2000; Phan et al. 2004; Phan et al. 2005). Defects in Lpin1 function 
cause lipodystrophy, hypertriglyceridemia and insulin resistance in mice (Peterfy et 
al. 2001), whereas overexpression of Lpin1 results in obesity (Phan and Reue 2005). 
In this study, we further examined the Lpin1 expression in mice carrying the wild-
type Lpin1 gene, as well as investigated the role of LPIN1 in human obesity, glucose 
and lipid metabolism (figure 10). 
STEP 1:
To study relationship between Lpin1
expression in adipose tissue, body 
weight and glucose metabolism in 
mice carrying a wild-type Lpin1 gene
STEP 2:
To investigate relationship between 
LPIN1 expression in human adipose 
tissue and BMI, as well as glucose 
and lipid metabolism
STEP 3:
To examine the variations in the 
human LPIN1 gene and their role in 
obesity, glucose and lipid metabolism
Figure 10. Overview of the aims in the study on the LPIN1 gene. 
The first part of this study investigated the Lpin1 expression in mice carrying a wild-
type Lpin1 gene. Two approaches were used to generate groups of mice having 
individual variation in glucose metabolism parameters and/or lipin expression levels. 
In the first approach, individual variation was introduced by producing a mixed 
genetic background in F2 mice derived from a cross between two inbred strains, 
C57BL/6J and BALB/cByJ. In the second approach, C57BL/6J mice were fed a high 
fat diet to promote the development of obesity, hyperglycemia and 
hyperinsulinemia.  
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In both mice strains, a negative correlation between lipin mRNA and fasting glucose 
levels was observed (Spearman correlation coefficient; r = -0.79, p < 0.0001 for 
mixed genetic background and r = -0.79, p < 0.0001 for C57BL/6J mice). Negative 
correlations were also observed between lipin expression and insulin levels (r = -
0.45, p < 0.04 for mixed genetic background and r = -0.64, p < 0.003 for C57BL/6J 
mice), and with the HOMA-IR index of insulin resistance (r = -0.66, p < 0.002 for 
mixed genetic background and r = -0.69, p < 0.0008 for C57BL/6J mice). The 
negative correlations were primarily due to effects in male mice. 
To determine whether similar relationships between lipin expression and metabolic 
parameters occur in humans, we quantified lipin mRNA levels in 19 human fat 
biopsies obtained from family members of the FCHL and low HDL-C families using 
DNA microarray analysis. Similar to the findings using mice, negative correlations 
were observed between human lipin mRNA levels and glucose (r = -0.81, p = 
0.001), insulin (r = -0.74, p = 0.001), HOMA-IR index of insulin resistance (r = -
0.82; p = 0.001), and TG levels (r = -0.64, p = 0.003). Thus, the negative correlation 
initially observed in mice between lipin expression levels in fat tissue and glucose, 
insulin, and HOMA-IR was also observed in humans.  
We next assessed whether specific alleles of the LPIN1 gene locus on chromosome 
2p25.1 were associated with human metabolic traits in dyslipidemic families, or with 
obesity in the study sample of obese cases and lean controls. Seven SNPs were 
genotyped and the LD among them was estimated using the founders in the 
dyslipidemic families and lean control individuals, see figure 11. None of the SNPs 
were redundant; however, some of them were in strong LD (D’>0.9) between each 
other as shown in figure 11. Altogether, the seven SNPs analyzed formed 8 different 
haplotypes with frequencies greater than 5% in these Finnish study samples. 
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Figure 11. Genomic structure of the LPIN1 gene and locations of the SNPs genotyped in 
the study. There are 20 exons in the LPIN1 gene (black boxes). The arrows on the bottom 
represent SNPs. Pairwise LD between each pair of 2 SNPs in the LPIN1 gene were 
obtained using GOLD program (Abecasis and Cookson 2000). D’-values are presented 
in the figure. SNP1 = rs893346, SNP2 = rs11693809, SNP3 = rs10192566, SNP4 = 
rs2278513, SNP5 = rs2577262, SNP6 = rs2716610, SNP7 = rs1050800.
The set of quantitative traits to analyze in dyslipidemic families were derived from 
the phenotype of the fld mouse (Langner et al. 1989; Reue et al. 2000). These traits 
included BMI, fasting TG, glucose and insulin levels, as well as lipoprotein lipase 
and hepatic lipase activities in all the family members (n = 1109). Females (n = 571) 
and males (n = 538) were also analyzed separately because these traits showed 
significant differences between genders in our study sample (p < 0.05). An 
association with serum insulin levels was observed with SNP2 (p = 0.008). The sex-
specific analyses showed that primarily males contributed to the association (p = 
0.01). In females, hepatic lipase activity was associated with SNP3 (p = 0.02). We 
also performed haplotype analysis of seven SNPs using FBAT program and 
observed evidence of association with insulin levels in males (p = 0.03). 
To characterize more thoroughly the alleles associated with insulin levels and 
hepatic lipase activity, we performed analyses using the FBAT program and 
monitored the transmission of different alleles and allelic haplotypes. The T-allele of 
SNP2 (with a frequency of 40%) was preferentially transmitted to those with 
elevated insulin levels and the G-allele of SNP3 (with a frequency of 55%) to those 
with elevated hepatic lipase activity. The most common haplotype 1 (A-T-C-T-G-C-
C) with a frequency of 20%, as well as haplotype 10 (A-T-C-T-G-T-C) with a 
frequency of 4%, were preferentially transmitted to those with elevated insulin 
levels. In contrast, haplotype 8 (A-T-C-T-A-C-T) with a frequency of 5% was 
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undertransmitted to those with higher insulin values. To obtain empiric p-values for 
the allelic haplotype analysis with SNPs in considerable LD, we permuted the 
analysis 100 000 times using the haplotype permutation option in the FBAT 
program. The association with insulin levels remained significant in males for the 
overall analysis of the 7 SNP haplotype (p = 0.04), as well as for haplotype 1 (A-T-
C-T-G-C-C, p = 0.05), haplotype 8 (A-T-C-T-A-C-T, p = 0.002) and haplotype 10 (A-
T-C-T-G-T-C, p = 0.008). 
We examined the association between LPIN1 genotypes and obesity in lean (BMI 
20-25 kg/m2) and obese (BMI > 30 kg/m2) Finnish subjects by testing the seven 
LPIN1 SNPs for differences in allele frequency between obese (n = 493) and lean 
individuals (n = 821). A difference in allele frequency was observed for SNP 6 (C/T)
(0.11 vs. 0.08 for the obese and lean, respectively, p = 0.02; odds ratio of 1.4; 95% 
confidence interval 1.04-1.86). We also analyzed the LPIN1 SNPs for differences in 
mean BMI levels between different genotype groups. SNP1, SNP5 and SNP6 were 
associated with BMI in lean males (p = 0.01, 0.008 and 0.03, respectively) and 
SNP2, SNP3, SNP4 and SNP5 in obese males (p = 0.04, 0.008, 0.008 and 0.002, 
respectively). Since no association was observed in lean or obese females, the 
association of LPIN1 alleles with BMI may be sex specific. 
In summary, we found evidence of a negative correlation between the expression levels 
of Lipin-1 and glucose, as well as insulin levels both in mice and humans. In humans, 
genetic variations of the LPIN1 gene were also associated with insulin levels and BMI in 
dyslipidemic families, as well as in obese case and lean control individuals, with males 
contributing most to the differences. This is the first study suggesting the involvement of 
the LPIN1 gene in glucose metabolism and BMI in humans.  
3 Fine mapping a locus linked to obesity on chromosome 
Xq24
The chromosome Xq24 region was previously linked to obesity in a genome-wide 
scan performed in 166 Finnish obese families including 367 affected individuals 
(Ohman et al. 2000). Other genome-wide scans in Finnish families have implicated 
this region in premature CHD (Pajukanta et al. 2000), and low HDL-C (Soro et al. 
2002), as well as in TC and apolipoprotein B traits (Pajukanta et al. 1999). In this 
study, the Xq24 locus was fine mapped in Finnish nuclear families in four steps to 
identify the gene predisposing to obesity (figure 12). 
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Figure 12. Overview of the 4-step strategy used in the fine 
mapping of the chromosome Xq24 region. 
In step 1, we first investigated the 15-Mb region by genotyping additional 
microsatellite markers and SNPs for regional candidate genes, and by testing them 
for linkage and association. The aim was not to cover all the genes located in the 15-
Mb region, but to target the relevant functional candidate genes for obesity (figure 
13). Altogether 36 SNPs in nine genes and nine microsatellite markers (figure 13) 
were genotyped in 100 obese sibpairs and in all available parents (figure 12). In step 
2, the genotyping was further extended to 118 additional sibpairs for the 9 
microsatellite markers and 17 SNPs in the AGTR2, SLC6A14, SLC25A5, NDUFA1
and HTR2C genes, representing the most promising findings in stage 1. 
In the linkage analysis of steps 1-2, most of the allele sharing among the obese sibs 
occurred over an 8-Mb region between the marker DXS6804 and the HTR2C gene. 
Interestingly, the obese male sibpairs contributed the most to the linkage signal in 
this region. 
STEP 1 - STAGE 1 LINKAGE STUDY: 
??188 affected siblings (BMI > 32 kg/m2) from 87 Finnish 
families and all the available parents 
STEP 2 - STAGE 2 LINKAGE STUDY: 
??250 additional affecteds (BMI > 30 kg/m2)  
??genotyped for the 17 most promising SNPs and 9 
STEP 3 – INITIAL ASSOCIATION STUDY: 
? 117 Finnish male probands from the families (=cases) 
STEP 4 – REPLICATION STUDY: 
? 841 obese cases from Finland and Sweden 
(416 females/425 males) 
? 968 lean controls from Finland and Sweden 
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Figure 13. The genes and microsatellite markers on chromosome Xq selected for the 
study. Distances and order of the markers and genes are based on the public NCBI and 
the commercial Celera Genomics databases. 
Because most of the linkage evidence of the SNPs and microsatellite markers in the 
Xq24 region emerged from the obese male sibpairs, haplotypes of all male sibpairs 
were analyzed. In the SLC6A14 gene, we detected putative haplotypes that were 
shared between the sibpairs in different families. These shared haplotypes of the 
SLC6A14 gene partially extended to the neighboring markers (DXS8053 and 
DXS8081) and genes (AGTR2, SLC25A5 and NDUFA1). Subsequently, for the 
initial association analysis, we selected 11 informative SNPs for the SLC6A14 gene 
and for its two neighboring genes (AGTR2 and SLC25A5) and also three 
microsatellite markers (DXS8081, DXS8053 and DXS8064) located in this region. 
In step 3, for the initial association analysis, the first genotyped obese male from 
each of the families was selected to represent cases (n = 117) and 182 lean unrelated 
males were selected as controls. The allele frequencies differed significantly 
between cases and controls for the SNP3 (p = 0.0002) and marginally for SNP2 (p = 
0.07) in the SLC6A14 gene. When combining these two intragenic SNPs into 
haplotypes, the difference in allele frequencies remained significant (p = 0.0007), as 
occurred when combining all three SNPs of the SLC6A14 gene (p = 0.006). The 
structure of the SLC6A14 gene and the locations of the SNP1, SNP2 and SNP3 are 
presented in figure 14. 
In step 4, the SNP2 and SNP3 of the SLC6A14 gene were genotyped in an 
independent replication sample of 837 obese cases (416 females / 421 males, table 
11 on page 48) and 968 lean controls (381 females/ 587 males, table 11 on page 48) 
from Finland and Sweden. Significant differences in allele frequencies were detected 
for SNP3 between the lean and obese groups (p = 0.003). Surprisingly, the opposite 
allele in comparison wih the initial association analysis (SNP3C) was more common 
among obese subjects in the replication study (allele frequencies of 0.49 in cases and 
0.43 in controls). For SNP2, the T-allele was more frequent in the cases than in the 
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controls, but the difference was not statistically significant (allele frequencies for T-
allele 0.38 vs. 0.35 for the cases and the controls, respectively, p = 0.08).  
One overall analysis combining the information of SNP2 and SNP3 was performed 
using Genetic Homogeneity option of the Mendel program (Lange et al. 2001). In 
this analysis, empiric p-values were calculated by permuting the case and control 
labels within the categories of Swedish males, Swedish females, Finnish males and 
Finnish females simultaneously, and combining the data for each permutation to 
establish a distribution of possible genotypes for cases and controls. The association 
with obesity was observed (p < 0.05), suggesting that a combined analysis of both 
SNPs provided evidence of association in the replication study sample.  
When investigating the SNPs separately in both sexes, the females were found to 
contribute most to the observed association (p = 0.006) for SNP3 with the allele 
frequencies of 0.48 in cases (n = 416) and 0.41 in controls (n = 381) for the C-allele.
The C-allele was more common among both the Swedish and Finnish obese groups 
(p = 0.08 and 0.03, respectively). 
The entire SLC6A14 gene, 800 bp of its proximal promoter, and 2 kb downstream 
from the 3’-end of SLC6A14 (including an adjacent predicted gene, LOC203413,
Genebank accession no. XM_117548) were sequenced in 20 obese male individuals. 
The sequence analysis of the SLC6A14 gene and its proximal 5’-promoter revealed 
two variants in the promoter, two in the coding region, four in the 3’-UTR and 41 in 
the intronic regions, in addition to the three SNPs genotyped earlier. None of the 
variants changed an amino acid. In the predicted LOC203413 gene, we found one 
SNP in the 3’-UTR of the gene and an insertion of four bases in intron 1. In total, 30 
of these variants were novel, not found previously in the public (NCBI, LocusLink) 
or commercial (Celera) SNP databases.  
Five additional variants (–715C/G and –298A/G in the putative SLC6A14 promoter, 
3401C/T in intron 2, 23041C/T and 24447A/G in exon 14) were genotyped for LD 
analysis in a subset of obese (n = 180) and lean (n = 180) Finnish males. The 
location of these five variants in the SLC6A14 gene is presented in figure 14. SNP2 
and SNP3 were in tight, but not in complete LD (p < 0.00001). Both of these SNPs 
were also in LD with the two SNPs in exon 14 (p < 0.00001). All four SNPs were 
located within a 4-kb region. The LD breaks down with the three SNPs in the 
promoter and in the intron 2 (p > 0.003), located 17-21 kb from SNP2. No difference 
was observed between the male cases and controls in the extent of LD. 
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Figure 14. The structure of the SLC6A14 gene and locations of the genotyped SNPs. 
To summarize, a novel candidate gene for obesity SLC6A14 was identified after fine 
mapping the Xq24 region previously linked to obesity, premature CHD and 
dyslipidemias (Pajukanta et al. 1999; Ohman et al. 2000; Pajukanta et al. 2000; Soro 
et al. 2002). Initially, linkage and shared haplotypes were identified in obese male 
sibpairs for this region. Subsequently, significant evidence of association between 
variations in the SLC6A14 gene and obesity was observed in two different study 
populations. The SLC6A14 gene represents the second novel candidate gene for 
obesity that was identified using positional cloning approach in humans. 
4 Locus for quantitative HDL-C on chromosome 10q11 in 
Finnish families with dyslipidemia 
The aim of this study was to better address the phenotype linked to chromosome 
Xq24. This region was previously linked to obesity and premature CHD, low HDL-
C, as well as TC and apolipoprotein B traits in Finnish families (Pajukanta et al. 
1999; Ohman et al. 2000; Pajukanta et al. 2000; Soro et al. 2002). Suggestive 
linkage for this region was also observed for, low-HDL-C, TC and apoB traits in 
dyslipidemic Finnish families (Pajukanta et al. 1999; Soro et al. 2002). In addition, 
five other chromosomal regions, including 2q31, 8q23, 10q11, 16q24.1-24.2 and 
20q13.11, were investigated. These five regions were previously linked to premature 
CHD, FCHL and low HDL-C trait in Finnish study samples (table 12). 
In previous genome scans for premature CHD, FCHL, low HDL-C and obesity, 
several chromosomal loci were identified that showed evidence of linkage to these 
traits in Finnish families (Pajukanta et al. 1999; Ohman et al. 2000; Pajukanta et al. 
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2000; Soro et al. 2002; Pajukanta et al. 2003), table 12). The aim of this study was to 
further investigate six of these chromosomal regions in an extended study sample of 
1109 genotyped individuals from 39 low HDL-C and 53 FCHL families. The regions 
included: loci for low HDL-C on 8q23, 16q24.1-24.2 and 20q13.11 (Soro et al. 
2002); a locus for premature coronary on 2q31 (Pajukanta et al. 2000); a locus for 
serum TGs on 10q11 (Pajukanta et al. 1999) and a locus for premature CHD and 
obesity on Xq24 (Ohman et al. 2000; Pajukanta et al. 2000). A total of 67 
microsatellite markers in these regions were genotyped and analyzed for qualitative 
and quantitative lipid traits. 
Table 12. Previous findings from genome wide scans performed in Finnish families. 
STUDY SAMPLE TRAIT LOCUS REFERENCE 
FCHL High TGs 10q11 (Pajukanta et al. 1999) 
Low HDL-C Low HDL-C 8q23.1 
16q23.3
20q13.32
(Soro et al. 2002; Pajukanta et al. 
2003)
Premature CHD CHD 2q31 
Xq24
(Pajukanta et al. 2000) 
Obesity Obesity Xq24 (Ohman et al. 2000) 
The 10q11 region was originally identified for high TGs in a qualitative linkage 
analysis (lod = 3.2) (Pajukanta et al. 1999). In the present study, this region provided 
significant evidence of the quantitative HDL-C (lod = 3.2) with the marker 
D10S1772 in the present variance component analyses. Since serum TG and HDL-C 
levels are highly inversely correlated, they may at least partially share the same 
genetic background. To better address this, a novel QTL association analysis was 
performed using quantitative HDL-C and TG together, in addition to HDL-C and TG 
traits separately. In these analyses, evidence of association with quantitative TGs 
was observed with D10S546, about 7 cM from D10S1772 (p = 0.0006), see table 13. 
For HDL-C the association analysis produced a p-value of 0.02 with marker 
D10S1790 located in the close vicinity of D10S546 (0.0 cM, 889 kb). Furthermore, a 
combined analysis of quantitative HDL-C and TGs produced a p-value of 0.008, 
again with marker D10S546 in the association analysis. No other regions were 
observed with lod scores of over 3.0. 
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Table 13. Results of the quantitative association analyses of low HDL-C and FCHL 
families on chromosome 10q11. 
a) The distance from the first marker. ns. indicates not significant 
In summary, a novel QTL for HDL-C was identified on chromosome 10q11. The 
markers in this region produced significant evidence of linkage with serum HDL-C 
levels, as well as provided evidence of association with serum HDL-C and TG 
levels. The data suggests that the locus on chromosome 10q11 harbors variations 
influencing the serum HDL-C and TG levels. 
p-values Locus Distance 
(cM) a HDL-C trait TG trait Combined HDL-C 
and TG trait 
D10S1233 0 ns. ns. ns. 
D10S604 0.10 ns. ns. ns. 
D10S1772 2.28 ns. 0.06 ns. 
D10S1793 2.38 ns. ns. ns. 
D10S1724 3.80 ns. ns. ns. 
D10S196 3.90 ns. ns. ns. 
D10S220 4.00 ns. 0.06 ns. 
D10S1220 4.10 ns. ns. ns. 
D10S568 5.73 ns. ns. ns. 
D10S1790 9.31 0.02 ns. 0.05 
D10S546 9.41 ns. 0.0006 0.008 
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DISCUSSION 
The aim of this thesis was to identify genes predisposing to obesity and related 
metabolic traits. Two types of approaches were applied: testing functional candidate 
genes for obesity and fine mapping chromosomal regions that have been previously 
linked to obesity, premature CHD or familial dyslipidemias. 
In the beginning of this thesis, five monogenic forms of obesity (defects in Leptin, 
Leptin receptor, POMC, ENPP1 and MC4R) were described (Jackson et al. 1997; 
Montague et al. 1997; Clement et al. 1998; Krude et al. 1998; Vaisse et al. 1998; 
Yeo et al. 1998). However, the proportion of morbid obesity that they explained in 
the population was unclear. As observed in the first part of this thesis, the mutations 
in the MC4R and POMC genes do not explain a substantial part of obesity in obese 
Swedish adults (I). Of these five genes, mutations in the MC4R are currently the 
most common known genetic cause of obesity, as up to four percent of obese 
individuals carry mutations in the MC4R gene (Farooqi et al. 2000; Vaisse et al. 
2000; Perusse et al. 2005). However, the studies reporting such high frequencies 
have focused on obese children or adults with early-onset obesity instead of obesity 
later in life. The mutations identified in these genes causing monogenic forms of 
obesity have been nonsense or missense mutations, resulting in a more or less non-
functional protein product.  
During the course of this thesis it became increasingly evident that the common 
forms of obesity are not caused by single gene mutations (Bell et al. 2005). The 
general focus of the research in obesity genetics has shifted from screening rare 
coding mutations in functional candidate genes towards searching for more common 
predisposing alleles or haplotypes in functional or positional candidate genes. 
Variants involved in the common forms of obesity are likely to result in minor 
changes in protein product or may reside in promoters or other regulatory regions 
(Mackay 2001; Korstanje and Paigen 2002; Thomas and Kejariwal 2004). The 
variants may cause small changes in the binding affinity of a transcription factor or 
slightly alter gene expression levels, timing and tissue specificity. Nutrients or other 
environmental factors may potentially also modulate differences introduced by 
genetic variation. Each of the individual variants is likely to cause subtle changes in 
the disease phenotype. However, both multiple predisposing genetic variants and 
environmental factors are suggested to contribute together to manifestation of 
symptoms, ultimately leading to the disease. 
The POMC gene is an interesting candidate gene also for the common forms of 
obesity. The chromosome 2p23.3 region, where POMC resides, was previously 
linked to BMI and serum leptin levels (Comuzzie et al. 1997; Hager et al. 1998; 
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Rotimi et al. 1999; Delplanque et al. 2000; Moslehi et al. 2003; Palmer et al. 2003). 
Variations in POMC were associated with serum leptin levels in Mexican-American 
families (Hixson et al. 1999). In our study sample of adult individuals from Sweden, 
the common polymorphisms in the promoter and in the 3’-UTR were associated with 
serum leptin levels in lean individuals. No such association was observed in obese 
individuals. Higher serum leptin levels are known to activate POMC containing 
neurons (Cowley et al. 2001) and induce POMC expression in the arcuate nucleus in 
the hypothalamus (Thornton et al. 1997). Functional variations in the POMC gene 
may possibly result in differential responses to leptin levels. A potential feedback 
signaling could then further enhance the leptin production to compensate for the 
reduced effect of the serum leptin on the function of POMC. The association 
observed only in lean individuals may suggest that the regulation of the leptin-
POMC system is important in normal weight individuals. However, other signals 
may override this regulation when body weight increases substantially. 
Recently, three studies with relatively large sample sizes have investigated the 
variations in the POMC gene (Baker et al. 2005; Chen et al. 2005; Sutton et al. 2005). 
All three studies detected associations with POMC polymorphisms and traits related to 
body composition (BMI, WHR, waist circumference, total fat mass and serum leptin 
levels). The 8246C/T variant in the 3’-UTR showed evidence of association in these 
three recent studies (Baker et al. 2005; Chen et al. 2005; Sutton et al. 2005), as well as 
in the previous study by Hixson et al. (1999) and our present study. However, opposite 
alleles were associated with obesity-related traits in different studies. This may reflect 
a different haplotype background of the study populations (Hixson et al. 1999; Baker 
et al. 2005; Chen et al. 2005; Sutton et al. 2005). 
LPIN1, residing in the 2p25.1, is another interesting candidate gene for obesity. The 
mouse homologue, Lpin1, was originally identified to cause lipodystrophy, insulin 
resistance and hypertriglyceridemia in the fld mice (Peterfy et al. 2001). Recently, 
overexpression of the Lpin1 gene was reported to promote obesity in mice (Phan and 
Reue 2005). No study has previously investigated the role of the human LPIN1 gene in 
obesity and related metabolic disorders. In the present study, a negative correlation 
was observed between LPIN1 mRNA levels in adipose tissue of the dyslipidemic 
individuals and fasting glucose levels, insulin levels, as well as HOMA-IR, an 
indicator of insulin resistance. The study was extended to investigate the variations of 
the LPIN1 gene. Evidence of association was observed between insulin levels and 
LPIN1 SNPs, and their haplotypes in the dyslipidemic families. The LPIN1 variants 
were also associated with BMI in the obese male cases and lean male controls. It 
would have been interesting to test whether the association with parameters of glucose 
metabolism is also present in obese and lean individuals; however, these parameters 
were unfortunately not available for the obese and lean individuals. In conclusion, the 
study provides evidence that the Lpin1 gene, identified in a spontaneous mutant mouse 
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strain with an aberrant metabolic phenotype, may also have relevance to human 
dyslipidemias and body weight regulation. 
Obese individuals represent a heterogenous group of individuals in regard to related 
diseases they exhibit (such as cardiovascular diseases, T2DM, dyslipidemias etc.), age-
of-onset, feeding behaviour, body composition and physical activity. By studying 
specific subgroups or individual traits related to obesity may make it easier to identify 
the underlying genetic variation(s). Obesity, metabolic syndrome, T2DM, disturbances 
in lipid and glucose metabolism often co-occur on same individuals. However, it is 
still not clear which is the underlying dysfunction. Genetic factors may predispose to 
any of these individual components and further result in obesity and related disorders. 
For this reason we also studied metabolic traits related to obesity. 
In this thesis, we fine mapped six chromosomal regions that were previously linked to 
obesity, premature CHD or familial dyslipidemias in Finnish families. Of them, 
chromosome 10q11 showed evidence of linkage (lod = 3.2) and association (p = 
0.0006) with quantitative HDL-C and TG levels in extended study sample of Finnish 
dyslipidemic families. Further studies are warranted to identify the underlying gene 
likely to confer susceptibility to high serum TG and low HDL-C levels in this region. 
The other regions including 2q31, 8q23, 16q24.1-24.2, 20q13.11 and Xq24 provided 
stronger evidence of linkage in the original study samples than in the extended 
families. This may reflect the risk of introducing genetic heterogeneity while 
extending the study sample to more distant relatives or additional families. This 
phenomenom has also been observed in other studies (Watanabe et al. 2000; 
Naoumova et al. 2003). However, the finding on chromosome 10q11 region may 
suggest that the underlying gene has a broader effect on HDL-C and/or TG levels. 
HDL-C and TG levels are highly inversely correlated and they may exhibit at leat 
partially shared genetic background. 
Obesity and related metabolic traits show sex-specific features (Harris et al. 1995; 
Pietilainen et al. 1999; Wauters and Van Gaal 1999; Lahti-Koski et al. 2000; Blaak 
2001), making X-chromosomal genes potential candidates for these phenotypes. The 
region on chromosome Xq24 was previously linked to obesity (Ohman et al. 2000), 
premature CHD (Pajukanta et al. 2000), as well as TC and ApoB traits in Finnish 
families (Pajukanta et al. 1999). Overweight predisposes to CHD and patients with 
CHD in turn are often obese (Hubert et al. 1983; Willett et al. 1995; Hu et al. 2005) 
and exhibit elevated serum TC and ApoB levels (Genest et al. 1992). It is thus 
tempting to hypothesize that allelic variants of the same gene may predispose to both 
of these traits. In the second part of this thesis, the region on chromosome Xq24 was 
fine mapped in the Finnish obese families and in the two study samples of obese 
cases and lean controls collected from Finland and Sweden. Variants in a novel 
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candidate gene for obesity, SLC6A14, showed evidence of association with obesity 
in the original and in the replication study samples. 
Very recently the association of obesity with SLC6A14 was replicated in a large 
French obese study sample (Durand et al. 2004). Interestingly, the SLC6A14 variants 
were also found to modulate differences in hunger and satiety scores among these 
French obese subjects. However, there were differences in the obesity-associated 
allele of the same variant, as well as in gender-specificity in the different study 
samples. Several explanations may account for these inconsistencies. The variants 
studied here so far may not be the functional ones, but instead they may reflect the 
causative variant(s) in close proximity. In a different ethnic and haplotype 
background the underlying LD pattern may be different. Different study samples 
may also be exposed to different environmental factors or display interactions with 
other genes. These potential gene-gene or gene-environment interactions and 
phenotypic heterogeneity may thus complicate the analysis. In addition, refining the 
phenotype associated with this gene is important when dealing with such a complex 
disorder as obesity. Considering that our original and replication study samples were 
recruited solely based on the BMI, these groups of patients may be phenotypically 
very heterogeneous. It is also possible that SLC6A14 harbors multiple variants, 
predisposing to different degrees of obesity. These variants may be unevenly 
distributed in the two groups of patients. The X-chromosomal inactivation in 
females may further complicate or add noise to the analyses of SLC6A14 located on 
chromosome Xq24. 
Based on its function, SLC6A14 is an interesting candidate gene for obesity. It 
encodes a sodium- and chloride-dependent transporter for neutral and cationic amino 
acids with high affinity for the non-polar amino acids such as tryptophan (Sloan and 
Mager 1999). Tryptophan is a precursor to serotonin, which is a neurotransmitter 
suggested to be involved in the signaling of satiety (Halford and Blundell 2000). 
Therefore, factors affecting serotonin concentrations, such as its precursor 
availability, could potentially have an effect on the appetite regulation and, thus, on 
the development of obesity. SLC6A14 is expressed in multiple tissues, including 
stomach, intestine, colon, salivary tract, pituitary gland, blood, liver, lung, mammary 
gland, muscle, pancreas, prostate and uterus. The gene could potentially modulate 
the amino acid absorption from the stomach or amino acid transport through the cell 
membranes and, thus, modulate the precursor availability for the serotonin synthesis. 
Figure 15 shows the most important regulators of appetite control together with 
proposed hypothetical sites of the SLC6A14 action. Interestingly, expression of the 
tryptophan hydroxylase, the rate-limiting enzyme of the serotonin synthesis, is 
detected in the pituitary gland in addition to other parts of the brain (Zill et al. 2005). 
Another possible hypothesis of the role of SLC6A14 in obesity is related to the 
thrifty phenotype hypothesis (Hales et al. 1991; Hales and Barker 1992; Barker et al. 
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1993) According to the thrifty phenotype hypothesis, unfavorable nutrition in utero 
affects the development of the body organs and leaves them susceptible to certain 
diseases related to nutrition and environment later in life, such as obesity, diabetes, 
metabolic syndrome and cardiovascular diseases (Barker et al. 1993). Since 
SLC6A14 is expressed in blastocysts in mice (Martin et al. 2003; Van Winkle et al. 
2005), and it is an important transporter of amino acids at this developmental stage 
of the fetus, it can be speculated that if the efficiency of the amino acid supply via 
SLC6A14 is affected by variations in the gene, it could further affect the availability 
of amino acids for the fetus in its early stage of development. 
The phenomenon where opposite alleles associate with the phenotype in different 
study samples, as observed here for POMC and SLC6A14, has also been observed in 
previous studies (Meirhaeghe and Amouyel 2004). The role of common variants in 
the PPARG gene has been studied thoroughly in context with T2DM. The rare ala-
allele of the pro12ala variant in the PPARG gene was originally reported by Deeb et 
al. (1998) to be associated with a lower BMI, improved insulin sensitivity and 
T2DM. Later studies have detected both a protective effect and a deleterious effect 
of the ala-allele in T2DM (Meirhaeghe and Amouyel 2004). In 2001, Altshuler et al. 
performed a meta-analysis on the pro12ala variant and T2DM and found a 
significant protective effect of the ala-allele for T2DM (Altshuler et al. 2000). To 
detect small effects that common variants may present, meta-analysis might be the 
way to proceed, in order to increase the power and decrease the chance of false 
positive and negative findings. Nevertheless, if the effects of certain variants are 
population or environment specific to a high degree, it may not be helpful to 
combine results from different populations. 
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SLC6A14
Amino acid absorption?
HYPOTHALAMUS
SLC6A14
Amino acid transport –
serotonin synthesis?
PITUITARY GLAND
Figure 15. Hormones controlling appetite. Leptin excreted from adipose tissue and 
insulin from pancreas decrease appetite. In the arcuate nucleus of hypothalamus, they 
inhibit neurons that produce Neuropeptide Y (NPY) and Agouti-related protein (AgRP) 
that stimulate melanocortin-producing neurons. Neuropeptide Y and Agouti-related 
protein are peptides that stimulate eating. The ?-melanocyte-stimulating hormone, 
produced by post-translational processing from pro-opiomelanocortin, is an endogenous 
ligand for melanocortin receptors MC4R and MC3R that signal for satiety. Ghrelin 
released from stomach stimulates appetite by activating NPY/AgRP-expressing neurons. 
PYY3-36 produced from colon acts through the Neuropeptide Y2 receptor and inhibits the 
NPY/AgRP neurons and, thus, decreases appetite. SLC6A14 is an amino acid 
transporter, but its potential role in the body weight regulation is not known. The 
potential sites of action include the intestinal track where it could affect the amino acid 
absorption. SLC6A14 is expressed in pituitary gland and might affect the amino acid 
transport and, thus, have an effect on the precursor availability for synthesis of certain 
neurotransmitters such as serotonin. Modified from (Schwartz and Morton 2002). 
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CONCLUDING REMARKS 
In the course of this thesis, important advances have been made in the tools and 
methods applied in searching genes predisposing to complex diseases. The first draft 
of the human genome sequence became available in 2001 (Lander et al. 2001; Venter 
et al. 2001) and the sequence was completed in 2003 by the HGP (Collins et al. 2003). 
The project provided initial information of the variations in the genome between 
individuals, and by now information of millions of SNPs (approximately 9 million by 
now) has been deposited into public databases. Rapid improvements in the SNP 
genotyping technologies have made it possible to genotype vast numbers of SNPs in 
extensive study samples. The International HapMap project, an extension of the HGP, 
has provided detailed information of the variation in the genome, LD structure and 
haplotype blocks, further facilitating the research aiming to identify genes associated 
with complex diseases (The International HapMap Consortium 2003). 
Obesity and related metabolic disorders are important diseases world wide, as they 
increase the risk of several other common diseases such as T2DM, CHD, 
hypertension, osteoarthritis and certain forms of cancer. Mapping the genes for 
complex disorders has turned out to be more challenging than initially expected. 
However, recent progress in obesity genetics, for example mapping the novel 
candidate genes through positional cloning approach, has shown the task to be 
possible (Boutin et al. 2003; Meyre et al. 2005a). The finding of the SLC6A14 gene 
in the present study presents the identification of the second novel candidate gene for 
obesity using positional cloning strategy. The recent replication of the initial results 
in an independent study population strongly suggests the involvement of the gene in 
obesity (Durand et al. 2004). A future task is to define the haplotype background in 
different populations and to identify the underlying causative variant(s) in the 
SLC6A14 gene. Ultimately, discovering the mechanisms by which the gene and the 
underlying variants are involved in body weight regulation may reveal novel 
molecular mechanisms underlying obesity, and ultimately provide new possibilities 
for treatment and prevention of obesity and related metabolic diseases. 
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